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Abstract 
The first objective of this dissertation was to develop metallated chelates with 
Michael acceptor groups for selecting small peptides from a random phage display library 
(RPL). The selection is for cysteine bearing peptides, so that the sulfhydryl on cysteine 
reacts with the reactive electrophilic group conjugated to the 1, 4, 7, 10- 
tetraazacyclododecane N, N’, N’’, N’’’, N’’’’–tertraacetic acid (DOTA) chelate. Upon 
selection of peptides with affinity for the radiochelates, the antibody-conjugated peptides 
are used in pretargeting tumors. Three radionuclides (68Ga, 111In, and177Lu) were selected 
for labeling DOTA due to their nuclear properties applicable for radiopharmaceuticals, as 
well as their ability to form unique coordination geometries with the DOTA chelate. The 
latter variance is expected to contribute to selecting a peptide that binds specifically to 
each of the three metallated complexes. The newly synthesized chelate 2,2',2'',2'''-(2-(4-
(4-amino-4-oxobut-2-enamido)benzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetrayl)tetraacetic acid (AmMABD) was radiolabeled with 68Ga and177Lu and the 
complexes were evaluated for their in vitro and in vivo stabilities and compared to 
previously reported radiolabeled complexes without electrophilic functional groups. The 
result from these studies showed the radiolabled (68Ga and 177Lu) AmMABD complexes 
were in vitro and in vivo stable. The encouraging biodistribution profile and fast blood 
clearance of the radioconjugates suggest that they are potential candidates for 
radiodiagnostic and radiotherapeutic agents. 
 The second objective of this dissertation focuses on separation and purification of 
radiolanthanides to achieve high specific activity radioisotopes applicable in nuclear 
  xv 
 
medicine. The reactor produced radiolanthanides, such as 177Lu, 161Tb and 166Ho, have 
nuclear properties useful for diagnoses and treatment. The low-energy β−emitters 177Lu 
and 161Tb are capable of causing cell damage, which is useful to localize and target 
metastasized large tumors.  These radioisotopes also emit low energy photons useful for 
gamma camera imaging. In contrast, 166Ho emit high energy β‐ particles to deliver higher 
doses of radiation for effective therapeutic applications. In order to utilize these 
radionuclides for targeted radiodiagnosis or radiotherapy, the product radioisotopes must 
be separated from the irradiated target and other impurities encountered in the production 
process. Of the different chemical separation processes explored, the separation by 
utilizing chromatographic media enabled the removal of the bulk of the irradiated targets. 
An alternative separation method that chemically reduces enriched Yb3+ targets and 
exploits the oxidation state differences between the Yb2+ and Lu3+ was also explored. 
This multistep separation of Yb2+ from 177Lu3+ is advantageous over chromatographic 
separation since it minimizes mixed radioactive wastes generated and lowers processing 
time.  A method to reduce Yb3+ to Yb2+ was developed, however due to the high potential 
of the Yb3+/Yb2+ redox couple (-1.05 V measured against Ag/AgCl reference electrode), 
reoxidation of the Yb2+ back to 3+ remains to be overcome. 
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Chapter 1 
1.1 Introduction to Development of Radiopharmaceuticals 
The development of radiopharmaceuticals involves preparation of molecules that 
contain radioactive atoms for potential applications in nuclear medicine. These 
radioisotopes with suitable nuclear properties can be used for diagnoses and/or therapy. 
Nuclear medicine takes advantage of radioisotopes that undergo radioactive decay to 
attain stability by releasing particles or electromagnetic radiations. The nuclear properties 
of a spontaneously decaying isotope, including its decay modes, the energies emitted, and 
the half-life, are fundamental in selecting radioisotopes for medicinal applications. 
Although these properties are discussed upfront, equally important are the production and 
availability of radioisotopes, the chemistry of the radioisotopes, and the molecules in 
which the radioisotope is incorporated.  
In 1898 Henry Becquerel was the first to report the biological effects of 
radioactivity after experiencing skin burn from exposure to radiation.1 This precedent led 
to an investigation of biological effects from radiation exposure and the application of 
radioisotopes in medicine.  In the early 1930s the construction of cyclotron accelerators 
by Earnest Lawrence revolutionized the technology of producing radioisotopes for 
pharmaceutical purposes. This investigation led to the development of radioisotope 
production for medicinal applications.2  
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1.2 Diagnostics and Imaging 
The radioisotopes utilized for diagnostics and imaging decay by emitting gamma 
or annihilation photons. The gamma photons are emitted if the nucleus is in an excited 
energy state above the ground state. The term isomeric transition indicates the decay 
pathway of gamma photon emission from an excited to a lower exited state to attain 
stability. Similarly, radioisotopes with their nucleus in an excited state can transfer 
energy to an electron from an inner orbital. This decay mode is termed internal 
conversion. The primary detection method utilized to register the incident photons 
emitted from a radiation source administered to patients is known as single photon 
emission computed tomography (SPECT). SPECT is used for radioisotopes that emit 
gamma photons with optimal energies in the range of 100-200 keV. However, 
radioisotopes with emitted energies lower or higher than the optimal range are currently 
being used for SPECT (e.g., 131I and 201Tl have γ photons of 382 and 71 keV, 
respectively).3-4 The difficulties experienced in SPECT are related to quantitative 
measurements of the regional radioactivity in vivo using external detectors. Only a 
fraction of the photons emitted from the radioactive source reach the external detector. 
Other photons undergo interactions within the tissue that result in loss of energy. Some 
are absorbed by the tissue, while others undergo a change in direction. These multiple 
problems of absorption and scattering make it very difficult to perform accurate 
quantitative measurement of regional radioactivity with conventional external detector 
systems in clinical nuclear medicine.   
The imaging modality that utilizes positron emission tomography (PET) from 
annihilation photons can minimize the aforementioned problems in using SPECT. The 
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detection of radioactivity in PET takes advantage of the physical properties of the 
radioisotopes that emit a positively charged electron (also known as a positron, β+). A 
nuclide with a high ratio of protons to neutrons (Z/N) than the stable nuclide decays by β+ 
emission or electron capture. At the end of the path of the β+, they will combine with 
electrons in the surrounding matter and undergo annihilation, with each event giving rise 
to two photons of 511 keV that are emitted in 180◦ apart from each other. Because of the 
nature of the physics involved in the coincidence detection of photons in PET, the 
scattering or absorptions of photons caused by surrounding tissues is easily avoided by 
applying attenuation corrections.  
1.3 Radiotherapy 
Radioisotopes that decay by emitting particles are used for therapy. The 
commonly utilized decay modes for therapy are α, β-, and Auger electrons. The 
radioactive atoms that undergo decay by releasing alpha particles (
2
4 He2+) are usually 
produced by heavy element radioisotopes (usually Z ≥ 83).5  Beta decay (β-) is a type of 
radioactive decay mode that allows the conversion of a neutron to a proton within the 
nucleus and releases negatively charged electrons.  The other ionizing radiation source is 
the Auger electrons, which are generated by filling the vacancy of the inner electron 
orbitals following electron capture or internal conversion decay modes. The choice of 
radioisotopes for radiotherapy considers the characteristics of the decay modes. Alpha 
particles deliver a high radiation dose over a short range (few cell diameters, 2-3) when 
compared with β- particles (tens of cell diameters depending on their energies). Since 
these radioisotopes are damaging to cells in vivo, the diseased cells are targeted by 
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biological molecules labeled with radioisotopes to deliver radiation doses to the intended 
targets. Beta particles are less densely ionizing and are more penetrating than alpha 
particles. Long-range ionzing radiation from β- decay delivers the desired radiation dose 
to cancer cells further removed from the delivery site. Conversely, cancer cells that are 
localized in small regions of the body can be treated with Auger electrons, which are low 
in energy.  For this type of decay mode to be utilized in radiotherapy, the radiolabeled 
compound must be delivered to the nucleus to receive the dose required for cell damage.  
Another important factor in considering radioisotopes for nuclear medicine is the 
half-life. The rate of decay of a radioisotope follows first order kinetics and is 
characterized by its half-life. That is the time necessary for one half of the radioactive 
atoms of a sample to decay. The relationship between half-life (T 1/2) and the decay 
constant (λ) is illustrated in Equation1-1. 
Equation 1-1. 
)2ln( 2/1 T  
The physical half-life of the radioisotope should exceed the biological molecule’s 
in vivo half-life for targeted diagnosis or therapy. These requirements are critical if the 
biological molecule is an antibody or large molecule that has a long circulation and 
clearance time. 
 1.4 Production of radioisotopes  
The majority of radioisotopes for medical applications are artificially produced by 
irradiating highly enriched targets. The production of radioisotopes in general can be 
classified as accelerator-produced or reactor-produced. Cyclotron produced radioisotopes 
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are bombarded with accelerated charged particles such as protons, deuterons, or α 
particles. Radioisotopes produced by this reaction are generally no-carrier-added because 
the radioisotope can be separated from the target since they are different elements. 
Reactor-produced radioisotopes are generated by neutron capture by a stable isotope. In 
this case target nuclei are bombarded with neutrons in a nuclear reactor to produce a 
radioisotope, which will generally decay by β- emission. The factors that affect routine 
production of radioisotopes are associated with the nuclear properties of the target and 
the desired radioisotope, the facilities needed to irradiate the targets, and the cost of 
routine production and shipment of radioisotopes.  Higher standards are set for purity 
levels in radiopharmaceuticals.  
1.5 Radiodiagnostic and therapy development and approaches 
Different approaches are utilized to deliver a formulation of radiolabeled compounds in 
the biological system. The differences mainly lie in the methodology utilized to deliver 
the dose to the desired destination with a minimum loss to other regions of the body. The 
three general approaches that are used to deliver radiation doses to intended targets are an 
integrated approach, the bifunctional chelate approach, and the pretargeting approach. 
Radiometals are frequently applied in diagnosis and therapy because of the established 
chelating ligands that can accommodate a host of metal ions. Since this study focuses on 
using radiometals, the examples used for the different approaches listed above are 
associated with radiometals.  The integrated approach (Figure 1-1 A.) involves a 
radiolabeled chelate where the metal is an integral (required) component, as is the 
chelate, for the drug to reach its destined target.6 The following commercialized 
radiopharmaceuticals can be used as example for the integrated approach for delivering 
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radiolabeled compounds to patients: 99mTc‐sestamibi (myocardial perfusion agent) 
and153Sm-EDTMP (palliative treatment of bone pain).7 Figure 1-2 shows the chemical 
structures of 99mTc‐sestamibi (a) and 153Sm-EDTMP (b). 
 
 
 
 
 
 
 
 
 
 
Figure 1-1. Schematic diagram of (A) the integrated approach, (B) the bifunctional 
chelate approach, and (C) the pretargeting approach 
 
Antibody/
peptide
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B
Antibody/
peptide
C
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Figure 1-2. Chemical structures of 99mTc-sestamibi (a) and 153Sm-EDTMP (b) 
1.6 The bifunctional chelate approach (BFCA) 
 Target specific radiotherapy contains a receptor specific targeting moiety such as 
antibodies, an antibody fragment, or peptide and a chelating moiety (Figure 1-1 B). The 
chelating molecules have a dual function, one capable of linking to biomolecules and the 
other to coordinate radiometals. These two functional parts of the molecule are joined 
covalently by linking groups. The linker additionally can be used to modify the 
pharmacokinetic properties of the radiopharmaceutical. The ideal BCA would contain a 
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targeting moiety that probes for cells of interest and a chelating moiety that coordinates a 
radiometal with nuclear properties suitable for imaging or treatment. The coordination 
chemistry of the radiometal will determine the geometry and chemical stability of the 
metal chelate. The chemical stability of a radiolabeled compound from the 
thermodynamic point view, as indicated in the following Equation 1-2, is obtained when 
the coordinating donor atoms match the hard/soft metal ligand interactions. Accordingly, 
hard metals form more stable complexes with hard ligands that have donor atoms such as 
oxygen and nitrogen and the soft metals form more stable complexes with soft ligands 
that have donor atoms such as sulfur and phosphorous.8 
ondissociati
nasscciatio
eq k
kK   
Equation 1-2 Rate equation for a general forward and reverse reaction 
For radioisotopes with short half-lives, the Keq has to be high enough for a 
complete association to obtain higher yields. However, more attention is given to the 
kinetic inertness that is determined by the rate of dissociation (kd). The kinetic inertness is 
important since the radiolabeled compound is administered to the body in nanomolar to 
picomolar concentrations where endogenous competing proteins acting as ligands are 
available at much higher concentrations and could cause the dissociation of the bound 
metal ion and potentially complex the radiometal. Figure 1-3 shows the chemical 
structure of some commonly used chelates that are used to radiolabel +3 and +2 
radiometals such as Ga3+, Cu2+, or Lu3+. While acyclic chelates (EDTA and DTPA) 
provide a faster complexation time, which is helpful for short-lived radioisotopes, the 
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macrocylic ligands (DOTA and NOTA) provide greater stability for the coordinated 
metal center and are the preferred complexing agents.9 
N N
NN
R COOH
COOHHOOC
N N
R COOH
COOH
R
NCS, COOH, NH2
R
R=
NN
HOOC
N
COOHHOOC
COOH
R
N N
HOOC
HOOC
COOH
R
DOTA NOTA
DTPA EDTA
 
Figure 1-3. The chemical structures of DOTA, NOTA, DTPA, and EDTA chelators that 
coordinate +2 and +3 metal ions are illustrated with functional groups (R-) available for 
synthesis to link with targeting biological molecules. 
1.7 Pretargeting approach  
The frequently experienced difficulty in BCA targeted radiation therapy derives from the 
poor pharmacokinetics of large biological targeting molecules such as antibodies. If the 
radiolabled biological targeting molecule takes longer periods of time to find its target, 
this will result in radiation exposure to vital organs.  The pretargeting approach separates 
the radioconjugate from the targeting vector, mainly antibodies, to minimize the injected 
radiation dose to normal tissues. The first step in pretargeting is the delivery of an 
antibody or a peptide that upon injection circulates in vivo, and is given time to reach its 
maximum accumulation at the target site, with the rest clearing the body. The 
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subsequently injected radioconjugate is then captured by the pretargeting module, while 
the unbound radioconjugate clears rapidly from the body. Figure 1-1 C illustrates the two 
separately administered components of pretargeting approach. 
Pretargeting is advantageous as it (1) spares radiolabeling of antibodies from 
harsh reaction conditions, (2) significantly reduces the radiation burden to the antibody 
therefore no time restrictions on the biodistribution of the Ab, (3) minimizes the time 
invested to radiolabel and purify compounds, and (4) allows the use of short-lived 
radioisotopes for hospitals that have limited access to isotope production. 
This dissertation describes two projects related to radiopharmaceutical chemistry: 
1)   An investigation of a new pretargeting approach that links radiolabeled conjugates to 
small peptides, which have high affinity for radioconjugates is described, including 
the in vitro and in vivo stability of the newly prepared radioconjugate that are useful 
in pretargeting. 
2)   The evaluation of the separation methods of 177Lu, 161Tb, and 166Ho from enriched 
targets using chromatographic, chemical and electrochemical methods is described in 
Chapters 3 & 4. 
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Chapter 2  
Selection of peptides from random phage display peptide 
library with affinity for metallated chelates  
Introduction 
Pretargeting is an extensively investigated approach for delivering radionuclides 
to target cells of interest. The difficulty in designing a biological molecule that has the 
ability to capture the radiolabeled chelate in vivo has been discussed by Orcutt and co-
workers.1 The biotin–streptavidin system that has been the most studied in pretargeting 
(K =1015 ) 2-6 links the preadministered antibody to the radioconjugates has been reported 
to have limitations. Primarily, the presence of endogenous biotin that competes for the 
preadministered streptavidin-antibody can result in occupying the available binding sites 
at nanomolar concentrations, blocking subsequently administered biotinylated 
radioconjugates. An additional unfavorable feature in using the biotin-streptavidin system 
for pretargeting is that the immunogenicity of streptavidin (SA) limits the 
preadministered SA-ab to a single use, which is often less than optimal. 
An alternative to the streptavidin-biotin system is to chemically engineer 
antibodies that assume dual responsibilities, i.e., target cells of interest and capture the 
second injected radioconjugate. A study reported by Meares et al. describes the use of an 
antibody engineered to trap specifically and permanently its cognate binder, the 
radioconjugate, which has a functionalized redox-reactive group.7-12 The development  
scheme relies on a Michael addition reaction that occurs between a cysteine of a bi-
specific monoclonal antibody 2D12.5 and an acryl-based functional group derivatized on 
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a 1, 4, 7, 10-tetraazacyclododecane-N, N’, N’’, N’’’-tetraacetic acid (DOTA) chelator 
(Figure 2-1).9 Two different types of interaction were observed for the antibody metal 
chelator binding. The antibody CHA255 were selective in binding benzyl-EDTA chelates 
with different coordinating metals (In3+ > Fe3+ > Cd2+ >  Sc2+ > Ga3+) .11 However, for the 
2D12.5 antibody, which binds DOTA complexed to various lanthanides, no selective 
metal binding was observed between the antibody and the metal centers and thus no 
difference in binding was noted between the different metals including copper, which is 
known to exhibit a much different coordination to DOTA than the lanthanides. The 
drawback of using an antibody and a radioconjugate as the coupling agents is that the 
binding interaction between antibodies and radioconjugates is monovalent and gains no 
avidity advantage for the radioconjugate to form a strong binding. A monovalent 
engineered antibody against a small molecule will remain bound to its ligand for an 
average period of a few minutes to a few hours13, whereas a biotin molecule will remain 
bound to streptavidin with a half-life of about 35 h.14 
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Figure 2-1. A schematic diagram showing the reaction between [Y3+] AABD 
(acrylamido benzyl DOTA) metallated with an antibody that contains cysteine positioned 
close to the encapsulated chelate to form a covalent bond. 
Building on the work described by Meares, this study proposed an alternative 
linking mechanism between pretargeting antibodies and the radioconjugates that could 
enhances the avidity interaction between the capturing moiety and the radioconjugate. 
Instead of using engineered antibodies for capturing the radioconjugates, this proposal 
embarks on using small short cysteine-bearing peptides. This new approach of using 
peptides as the radioconjugate capturing moiety is expected to occur at a faster rate since 
the reactive thiol of the antibody is not in an optimal position for the required 
nucleophilic attack. Due to difficulties in determining “the perfect” amino acid sequence 
that weakly interacts with the derivatized radioconjugates and will bind covalently at the 
Michael acceptor site, a combinatorial searching method was employed. Figure 2-2 
shows the chemical structure of the DOTA type chelator that has a functionalized 
Michael acceptor group. 
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Figure 2-2. A DOTA type chelator that contains two functional moieties: the chelator DOTA 
(pink shading), which can be metallated with various radionuclides useful for in vivo imaging or 
therapy; and the Michael acceptor (green shading), which serves as a chemical “fastener.” The 
Michael acceptor couples covalently to the thiol group of the amino acid cysteine. 
 The selection of small peptides using phage display techniques is a powerful tool 
to identify peptide sequences that successfully bind the selector (metallated ligand).15-16 
The advantage of choosing small peptides over streptavidin for binding the second 
injected radioconjugate would have important advantages: (1) they are easy to couple 
chemically to most targeting modules; (2) they can be synthesized chemically making 
fully synthetic pretargeting probes possible, which would be resistant to proteolytic 
degradation; (3) they will not be immunogenic, and therefore can be used more than once 
in the same subject;  and (4) a single ‘generic’ peptide could be used with numerous 
stable, non-radioactive antibodies. 
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As was indicated from the Meares publications, the engineered antibodies (Ab) with 
cysteine are potential candidates for pretargeting.  The affinity binding can be enhanced if 
the Ab has a cysteine at an optimal position to obtain fast binding of the radioconjugate. 
The task to find an amino acid sequence with an optimal conformation for binding the 
radioconjugate is tedious. This study, therefore, utilized an established technique to 
rapidly screen effective magic peptides from a huge library of random peptides displayed 
on phage particles that have affinity for the metallated selectors. Figure 2-3 illustrates a 
phage particle that displays a random amino acid sequences designated as ‘X’ and fixed 
amino acids are coded in single letters. 
 
Figure 2-3. A random phage display library containing 12 random amino acids. Each 
displayed peptide would have a sequence of the form CXXXXXXXXXXXX and is 
susceptible to cleavage by enzyme trypsin.   
Modification of Chelates selected for radiolabeling. From the list of chelates 
functionalized with electrophilic groups that were evaluated by Meares, we have chosen 
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one with a weak electrophilic group, (S)-2-(4-(cis-3-carboxyacrylamido) benzyl)-DOTA 
[MABD]9. The factors that contributed to select the weak Michael acceptor instead of the 
strong one are two-fold. A peptide selected against weak Michael acceptor chelates is 
anticipated to have the conformations necessary to bind the selector molecule. A peptide 
that only binds strong Michael acceptor chelates (if the selection was performed using 
strong Michael acceptor chelates) could face stiff competition from endogenous proteins 
with strong nucleophiles by binding all the Michael acceptor radioconjugates that are 
only administered in small concentrations.  Second, the selection of peptides from the 
random phage display library requires the selector metallated chelates to be tethered on a 
solid support. The MABD has a functional group that lends a free carboxylic acid for 
attaching a moiety such as biotin to immobilize the entire selector molecule on a plastic 
material coated with streptavidin (Figure 2-2). Another diagram (Figure 2-4) is shown to 
represent a selector molecule with three important components: the metal ion, the 
coordinating chelator with a Michael acceptor group, and a biotin tag.   
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Figure 2-4. A structure that represents the selector molecule. A functinalized DOTA 
chelate metallated with either Ga3+, In3+, or Lu3+ ion. This molecule is also tagged with 
biotin for imoblizing the selector to a plastic plate coated with streptavidin to conduct the 
selection. 
The functional groups that have to be linked to the DOTA chelate, in addition to 
the Michael acceptor molecule, are compounds that have a high binding affinity to the 
immobilizing plastic support. A common practice in phage display selection is to 
synthesize biotinylated biological molecules to take advantage of the high binding 
affinity between biotin and the streptavidin coated plastic material. In this study biotin 
was attached to the DOTA type chelate in a position that does not affect the binding 
between the metal and the chelate. Also, since the reaction media for the selection was 
aqueous, PEGylated biotin was chosen for the biotinylation of the selector molecule. 
Figure 2-5 shows the structure of the entire selector molecule with the tagged biotin for 
capturing the selector onto streptavidin coated plates. 
Michael acceptor 
group 
Chelate 
Biotin 
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Figure 2-5. The metallated (Ga3+, In3+,  and Lu3+) MABD-PEG-Biotin complex are the 
selector compounds. The yellow colored cartoon is biotin for capturing the selector 
compound on a plastic plate coated with streptavidin. 
This modification of the metallated selector molecule (MABD-PEG-Biotin), 
however, does affect the structure of the MABD at the carboxylic acid terminus, where 
the biotinylated MABD-PEG-Biotin has an amide between the PEG and the Michael 
acceptor. It is important to note here that once the selection process is completed the 
selector molecule [M] MABD-PEG-biotin is no longer required for the pretargeting 
studies. Instead, the MABD with a carboxylic acid terminus will be the one used in the 
radioconjugate molecule. The structural differences between MABD and the selector 
molecule [M] MABD-PEG-biotin may become problematic for the performance of the 
selected peptides in the pretargeting applications. So, a similar DOTA type chelate with 
an amide terminus was prepared to evaluate its in vivo and in vitro stabilities. 
Accordingly, the carboxylic acid terminus of MABD was converted to an amide terminus 
to form maleamic amino benzyl DOTA (AmMABD) that more closely resembles that of 
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the corresponding selector in terminating with an uncharged amide rather than a charged 
carboxylic acid.  
Geometric conformation of metal complex promotes selection of peptides. This study uses 
three selector and one counter selector compounds that are prepared by metal ion (Ga3+, 
In3+, and Lu3+) complexation with DOTA type ligands with distinct different coordination 
geometries for each metal. The Ga3+ and In3+ DOTA complexes have a coordination 
number of 6 and 7, respectively,17-18 whereas Lu3+ has a coordination number of 9 when 
complexing DOTA chelates with four nitrogen and four oxygen from the DOTA chelate 
and one water molecule.18 Figure 2-6 shows the complexation of the three metal ions 
(Ga3+, In3+, and Lu3+) to MABD. Such different three dimensional configurations could 
prompt selection of unique amino acid sequences from a random phage display library 
for each of the metal complexes.  
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Figure 2-6. Chemical structures of Ga3+, In3+, and Lu3+ MABD compounds in A, B, and 
C, respectively. 
The nuclear properties of the radioactive analogues of these metals are equally 
important considerations for imaging and therapy. The generator produced 68Ga (t ½ = 68 
m; β+ max 1900 keV) radionuclide decays by emitting a positron that upon annihilation 
with an electron forms two 511 keV photons, which can be used for imaging by positron 
emission tomography (PET).19  The accelerator produced 111In (t ½  2.8 d, γ 170, 250 
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keV) is used as the SPECT imaging surrogate of 90Y (t ½  2.7 d, β- max 2.28 MeV); a 
therapeutic radioisotope that only emits β- and not a traceable photons. The reactor 
produced 177Lu (t ½ = 6.7 d; γ 208 keV; β- max 0.5 MeV) decays to its ground state 177Hf, 
and emits both gamma rays and beta particles desirable for imaging and therapy.20  
Counter-selection of phage clones from the RPL 
Before selecting phage-borne peptides that couple to the Ga3+, In3+ and 
Lu3+MABD-biotin selectors, the goal was to deplete the phage peptide library of those 
peptides that couple to the Ca2+ MABD-PEG-Biotin counter-selector. The reason for 
counter-selection is to simplify preparation of radioactive MABD for administration to a 
subject. When chelators are labeled with radioactive metals, the metal is in a vast molar 
deficit compared to the chelator. When MABD is reacted with radioactive Ga3+, for 
instance, only a tiny fraction of the MABD is metallated. The goal is to avoid having to 
separate that tiny fraction from unmetallated MABD. The strategy is to metallate all non-
radio-metallated MABD with a vast excess of non-radioactive Ca2+, an ion that is 
abundant in blood and natural body fluids. In order to implement this strategy, we must 
ensure that the peptides that couple themselves effectively to Ga3+, In3+ or Lu3+MABD do 
not couple to Ca2+MABD, even when the latter is in vast molar excess. In view of the 
substantial differences in three-dimensional structures between Ca-MABD and the other 
chelates, it is not unreasonable to imagine a magic peptide that could discriminate 
between them. That is the reason for counter-selection with Ca2+-MABD-biotin, and 
Figure 2-7 depicts the advantage of the counter-selection by giving an example where 
unmetallated DOTA type chelates could easily form complexes with endogenous Ca2+ 
ions that are present at higher concentrations compared to the administered chelates. The 
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presence of the unmetallated chelate does not interfere with the biodistribution, since the 
preadministered peptide is selective for the Ga3+, In3+ or Lu3+MABD complexes.  
 
Figure 2-7. This figure illustrates the advantage of using peptides that preferentially 
binds the Ga3+, In3+ or Lu3+MABD complexes and not the unmetallated MABD. The 
counter-selection process would enable depletion of the library that binds Ca2+MABD-
PEG-Biotin 
Positive Selection of phages from the RPL. Three separate positive selection series were 
carried out in parallel, one series with each of the three positive selectors: Ga3+, In3+ or 
Lu3+MABD-PEG-Biotin. The input to the first round of all three series was the counter-
selected library described above; the input to each subsequent round of a series was the 
output of the previous round in that series.  
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Figure 2-8. An illustration of selection process: steps 1 and 2  involves the input virions reaction 
with the appropriate selector Ga3+, In3+ or Lu3+MABD-PEG-Biotin; in step 3 the reacted phage 
would then be captured by the streptavidin via the biotin tag; and in step 4 the captured phage is 
released by reaction with the trypsin enzyme to amplify the phages using E. coli cells.  
Project Objectives  
The project is classified into two parts. The first project is to synthesize chelates 
that have the Michael acceptor functional groups, coordinate them with radiometals, 
evaluate their in vitro and in vivo stability. The second part is to find peptides that have 
high affinity for the metallated conjugates from a random phage display library. 
Two ligands were prepared that have a Michael acceptor group, one terminating 
with a carboxylic acid (MABD) and the other with an amide (AmMABD). The position 
of the carbon-carbon double bond on the amidobenzyl-DOTA chelator affects the rate in 
which the thiolate (a strong nucleophile) forms a stable covalent bond with the carbon of 
the double bond (a very weak electrophile). The incorporation of such a functionality 
enables pretargeting peptides to capture the metallated complex. The radioconjugate with 
weak electrophilic functional groups may encounter strong nucleclophiles in the blood, 
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creating unwanted competition with the preadministered peptides. Such undesirable 
interactions between potent nucleophiles in the blood or tissues and the radioconjugate 
could nullify the use of these radioconjugates in pretargeting. Therefore, in vitro and in 
vivo stability studies on the 68Ga and 177Lu AmMABD radioconjugates were performed 
and are reported herein. Additionally, a comparison of the biodistribution results in 
normal mice with published biodistribution profiles of similar radiolabeled hapten 
molecules to determine the viability of the radioconjugates in pretargeting is described. 
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2.1 Experimental 
2.2.1 Chemicals and Reagents. The starting material (S)-2-(4-aminobenzyl)-DOTA 
tetra-tert-butyl ester (ABD-(t-Bu4)) was purchased from Macrocyclics (Dallas, TX). 
Maleic anhydride and other reagents, if not specified, were purchased from Fisher 
Scientific (St. Louis, MO). Maleamic acid was purchased from Sigma Aldrich (St Louis, 
MO). A 68GaCl3 generator was purchased from Eckert & Ziegler Isotope Products, Inc. 
(Berlin, Germany) and 68Ga was eluted with 0.1 N high purity HCl. Lutetium-177 
chloride (177LuCl3) was obtained from the University of Missouri Research Reactor 
(MURR) in 0.05 M HCl. Hydroxyapatite (microcrystalline hydroxyapatite 40% by 
weight in cross linked 4% beaded agarose) was purchased from Sigma Aldrich (St. Louis, 
MO). 57CoCl2 (specific activity 8.433 Ci/mg, t ½  271 d; γ 122 KeV) was purchased from 
PerkinElmer (Boston, MA) in 0.1 M HCl with specific activity of 8.433 Ci/mg. HPLC 
grade reagents were obtained from Fisher Scientific, (St. Louis, MO).  All chemicals 
were used as received unless otherwise stated. Mouse serum was purchased from 
Innovative Research (Novi, MI). Aqueous solutions were prepared with an in-house 
Milli-Q water system (Millipore Corp., Bilerica, MA). 
HPLC methods. HPLC analysis was performed on either a Beckman Coulter System 
Gold chromatograph equipped with a 168 diode array detector (Beckman Coulter, 
Fullerton, CA) or a Varian Prostar HPLC system.  A reversed phase C-18 Vydac (4.6 × 
150 mm, 5 μm, 100 Å) column was used for analytical HPLC analysis. A reversed-phase 
C-18 Jupiter column (10 x 250 mm, 5 μm, 300Å) purchased from Phenomenex 
(Torrance, CA) was used for semi-preparative work. The flow rates for analytical and 
semi-preparative experiments were 1 mL/min and 4 mL/min, respectively, while the 
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wavelengths were set at 214 nm and 280 nm for both. HPLC methods for (1) semi-
preparative purification and (2) analytical evaluations were as follows: (1) (A) 0.1% 
trifluoroacetic acid in water and (B) 0.1% TFA in acetonitrile with a gradient of 40-70 % 
of B over 45 min. (2) (A) 0.1% TFA in water and (B) 0.1% TFA in acetonitrile with a 
gradient going from 3-60% of B over 45 min. 
2.2.2 Synthesis of (s)-2-(4-(cis-carboxylamido)benzyl)-1,4,7,10-tet-razacyclododecane-
N,N’,N’’,N’’’-tetraacetic Acid (MABD). The synthesis method of the MABD compound 
was analogous to what was reported previously.9 Briefly, ABD (t-Bu)4  (100 mg, 0.14 
mmole) was added to 2 mL of dimethylformamide (DMF) solvent in a 10 mL conical 
vial. N, N-diisopropylethylamine (DIPEA) (22 μL, 0.1 mmole) was then added and the 
reaction mixture was stirred for 30 min. To the ABD (t-Bu)4 solution a 1.6 molar excess 
of maleic anhydride (12 mg, 0.1 mmole) was added dropwise and the reaction mixture 
was then stirred under argon for 24 h. The solvent was removed under reduced pressure. 
The dried product was dissolved in 10 mL of dichloromethane, and 5 mL of 0.1 M 
sodium bicarbonate solution was added to hydrolyze the unreacted maleic anhydride. 
While the target molecule remained in the organic phase, the hydrolyzed maleic acid was 
extracted into the aqueous phase. The extracted MABD (t-Bu)4 was dried over anhydrous 
Na2SO4, and the solvent removed by vacuum to yield the crude product. A fraction of the 
crude product was removed for analysis using LC/ESI-MS and  1H NMR (Figure A 2-2 
and A 2-3). ESI/MS C43H69N5O11 : m/z  calculated (MH)+ 831.5 g/mole, found 832.3 
g/mole;1H NMR  (500 MHz, CDCl3, δ ppm): 1.4-1.7 (s = 36 H), 1.80-3.6 (m= 25 H), 
5.85 (d, J = 13 Hz, 1H), 6.35 (d, J = 13.5 Hz, 1H), 6.36 (d, J = 8 Hz, 1H), 6.86 (d, J = 8.5 
Hz, 1H), 7.65 (d, J = 7 Hz, 2H), 14.76 (d, J= 28.5 Hz, 1H). In order to deprotect the 
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tertiary ester groups from the DOTA chelates to obtain four carboxylic acid groups, the 
solid product was dissolved in 800 μL of a cocktail mixture of  trifluoroacetic acid, 
triethylsilane, and water  with a ratio of 90/5/5 (TFA/TIS/H2O), respectively. After the 
deprotection, the solvent volume was reduced under a stream of N2 gas. To the resulting 
solid product 2 mL of a mixture of H2O/ACN (50/50) was added; the product was then 
precipitated with 500 μL of cold diethyl ether, and re-dissolved in a H2O/ACN (50:50) 
mixture for reversed-phase HPLC analysis. The crude mixture was purified by HPLC 
using a semi-preparative reversed phase C-18 column, and the fractions of the target 
molecule were collected and lyophilized. (ESI-MS C27H37N5O11 (Figure A 2-4): m/z 
calculated (MH+): 608.26. Found: 608.2 g/mole (Figure A 2-3).  
2.2.3 Synthesis of (s)-2-( 2-(4-(4-amino-4-oxobut-2-enamido)benzyl)-1,4,7,10-
tetrazacyclododecane-N, N’, N’’,N’’’-tetraacetic Acid (AmMABD).To the ABD (t-Bu)4  
(28 mg, 0.34 mmole) mixture in basic solution (preparation described above), previously 
prepared 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC),  N-
hydroxysuccinimide (NHS; 0.34 mmole, 56 mg), and  maleamic acid (40 mg, 0.34 
mmole) were added in 1 mL of DMF . The reaction mixture was stirred overnight under 
argon. The solvent was removed under reduced pressure and the product was dissolved in 
dichloromethane and dried over anhydrous Na2SO4. The crude product (28 mg of 
AmMABD) was dissolved in water and the tertiary protecting groups of the carboxylic 
arms were removed by following the same procedure as described above.14 The crude 
mixture was purified by HPLC using a semi-preparative reversed phase C-18 column, 
and the fractions of the target molecule were collected and lyophilized. (ESI-MS 
C27H38N6O10 m/z calculated (MH+): 608.28 g/mole; found: 608.35 g/mole)  (Figure A  2-
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-4). 1HNMR (500 MHz, D2O) δ: 4.2-2.9 (m = 25 H), 7.05 (d, J = 13.8 Hz, 1H), 6.29 (d, 
J= 13.8 Hz, 1H), 7.49 (d, J = 7 Hz, 2H), 7.27 (d, J = 8 Hz, 2H) (Figure A 2-5 and A 2-6). 
2.2.4 Radiolabeling. The solid MABD and AmMABD ligands were dissolved in 0.1 M 
NH4OAc at pH 5 to final concentrations of 2.8 μg/μL and 3.6 μg/μL, respectively. 
Radiolabeling with the generator-eluted 68GaCl3 in 0.1 N HCl was conducted by mixing 
500 μL of the 68Ga solution into a vial containing 800 μL of 0.4 M NH4OAc pH 5 buffer 
and 20 μL of the ligand with  subsequent microwave heating of the reaction mixture for 1 
min at a power setting of 100 watts. For the 177Lu labeling, the solutions containing 20 μL 
of the ligand and 150 μL of 0.1 M NH4OAc buffer were mixed with 20 μL of 177LuCl3 in 
0.05 N HCl and heated for 1 h at 100⁰ C. The radiolabeling yield was evaluated by radio-
TLC using C-18 reversed-phase plates analyzed using an AR-2000 Bioscan. The 
developing solution was 0.1 M NH4OAc: MeOH (50:50). The radiolabeled chelates 
travel toward the solvent front (Rf = 0.7), whereas the free radioisotope remains at the 
origin (Rf = 0).  
2.2.5 Serum stability studies. The stability of the 68Ga and 177Lu labeled MABD and 
AmMABD chelates in rat serum was determined following a referenced report that 
measured the extent of the transchelation of the radiometals from the chelates to the 
serum proteins.21 The radiolabeled complexes (50 μL) were incubated in serum (450 μL) 
at 37 ⁰C for up to 4 h for the 68Ga complexes and out to 6 days for the 177Lu complexes. 
The evaluation of intact complex was performed by spotting 1.5 μL aliquots for each time 
point on silica-gel fluorescent active TLC plates and developing with the mobile phase 
stated above. Under these conditions the radiolabeled complex moved with the solvent 
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front (Rf = 0.7 while free and serum protein bound 68Ga or 177Lu complexes remained at 
the origin (Rf = 0).  
2.2.6 Hydroxyapatite challenge study. Hydroxyapatite (HA) challenge was performed by 
mixing HA (0.5 g) with 2 mL of 50 mM Tris buffer solution (pH 7.8) and incubating in a 
water bath maintained at 37° C.22 In two separate vessels that contained the HA solutions, 
50 μL of the 177Lu MABD or 177Lu AmMABD were added and incubated for a time 
period extended out to 6 days. The samples were passed through 0.2 μm filters and were 
washed three times with milli Q water. The stability of the radiolabeled compound in HA 
challenge is expressed in percent by taking the ratio between the counts from the eluted 
solution and the HA bound radioisotope.  
2.2.7 Biodistribution. Biodistributions of the radiolabeled 68Ga AmMABD and 177Lu 
AmMABD conjugates were determined after intravenous administration in normal mouse 
models employed for drug discovery (n=3). All animal studies were performed under 
protocols approved by the University of Missouri Animal Care and Use Committee. 
Twelve normal adult CF-1 mice were injected with 68Ga AmMABD (42 μCi/100 μL) 
radioconjugate. A group of three mice were sacrificed by cervical dislocation at the 
specified time points (15 m, 30 m, 2 h, and 4 h) and organs of interest were harvested to 
measure radioactivity of the samples in a γ-counter together with a series of dilutions of 
the injected material to determine the percent injected dose per gram. Similarly, another 
fifteen adult CF-1 mice were injected with 22 μCi/100 μL of 177Lu-AmMABD conjugate 
and groups of three mice were sacrificed as described above at the specified time points, 
and organs of interest were measured for activity in a γ-counter. 
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2.2.8 Synthesis of MABD-PEG-Biotin. The diagram for the synthesis of MABD-PEG-
Biotin by utilizing solid phase peptide synthesis is shown in Figure 2-9. The MABD (t-
Bu)4 was prepared using the procedure listed under section 2.2.2. Briefly, ABD (t-Bu)4 
(100 mg, 0.14 mmole) was dissolved in 2 mL of dimethylformamide and to this mixture 
DIPEA (N,N-diisopropylethylamine) (22 μL, 0.1mmol) was added and stirred under 
argon. After 30 min of stirring, 1.6 equivalent of maleic anhydride (21.8 mg, 0.2 mmol) 
was added to reaction drop wise and continued to stir for 24 h. The solvent was removed 
under reduced pressure and the resulting crude product was dissolved in 
dichloromethane, mixed with NaHCO3, and vortex agitated to extract the unreacted 
maleic acid from the reaction mixture into the aqueous phase. This extraction was 
performed using a separatory funnel to isolate the product in the organic phase from the 
aqueous layer. The solvent of the organic layer was removed under reduced pressure and 
the resulting product was analyzed by LC/MS to determine the target molecule. A 
reversed phase C-18 column was utilized to evaluate the compound synthesis of 
MABD(t-Bu)4 using the following mobile phases with gradient flow at 1 mL/min. [(A) 
0.1% TFA in water and (B) 0.1% TFA in ACN with a gradient 3-60% for 45 min of B in 
A]. The MABD(t-Bu)4 crude product (80 mg, 0.096 mmole) was dissolved in 2 mL of N-
Methyl-Pyrrolidone (NMP) and 1.5 equivalents of benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) (150 mg, 150 µmol) was 
added and vortexed for 20 min to allow the formation of active ester at the carboxylic 
acid terminus. To this reaction mixture PEG-biotin resin was added (preparation of PEG-
biotin is described below) and vortexed for a further 26 h. The crude sample was filtered 
to remove uncoupled MABD (t-Bu)4 residues as well as activating reagents. Treatment of 
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the MABD (t-Bu)4-PEG-Biotin resin with trifluoroacetic acid removed the protecting t-
butyl esters from MABD(t-Bu)4-PEG-biotin and cleaved the MABD-PEG-biotin from the 
resin. An aliquot of the crude MABD-PEG-biotin compound was analyzed by LC/MS 
and the solvent of the reaction mixture was removed by evaporation under reduced 
pressure. The product was confirmed by ESI/MS. (expected mass M=  1035.49 g/mole: 
found  M+ = 1036.5 g/mole) (Figure A 2-7).   
 
Figure 2-9. Diagram of the reaction scheme for the formation of MABD-PEG-Biotin 
2.2.9 Determination of level of substitution of PEG-Biotin resin. Manufacturers’ 
declared substitution level of the biotin-PEG Nova tag resin™ (0.20 - 0.50 mmole/g resin) 
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was determined from the amount of Fmoc-chromophore liberated upon treatment of the 
resin with piperdine/ dimethylformamide.23 Briefly, Biotin-PEG-resin (100 mg) was 
treated with 1 mL of 25% piperidine in dimethylformamide for 1 h to cleave the Fmoc-
chromophore. The filtered Fmoc-chromophore solution was diluted 1 to 10 in N-
methylpyrolidone (NMP) and 20 μL aliquots were injected on a C-18 reversed-phase 
column. Fmoc-Gly/Sieber amide resin standards of known amounts were used as 
standards to determine the amount of Fmoc-chromophore that was released from the 
biotin-PEG resin by comparison of the chromatography peak area of Fmoc-chromophore 
with the standard. The experimentally determined value of biotin-PEG Nova tag resin™ 
(0.45 mmole/g of resin) was in accordance with the manufacturers’ claim.23  
2.2.10 Quantification of MABD-PEG-Biotin using isotope dilution analysis. A freshly 
prepared solution of 0.4 mM CoCl2 (23.6 μL, 22.4 mmol) using a cobalt reference 
standard solution was spiked with 5 μL of the 57Co activity (0.1 M HCl, 54.21 mCi/mL). 
This solution was added to reaction vessels that contained known amounts of MABD-
PEG-biotin in 0.1 M NH4OAc pH 5 buffer. The reaction mixture was vortexed for 5 min, 
an aliquot from each solution was taken out to spot silica-gel TLC plates, and the plates 
were developed with a 0.1 M NH4OAc pH 5 buffer. The [57Co] Co-MABD-PEG-biotin 
complex migrated to the solvent front on the TLC plate, whereas the unreacted/free 
[57Co]CoCl2 remained at the origin. The plates were cut in two pieces, 2 cm from the spot 
and each piece was counted for activity on a NaI (Tl) detector. The counts from the 
samples for various concentrations of Co2+MABD-PEG-biotin were plotted as labeled 
MABD-PEG-biotin vs concentration of the radiolabeled compound (Table 2-1). 
 
34 
 
 
0.1 M 
NH4OAc 
MABD-
Biotin 0.4 mM 57Co MABD-
Biotin  
mM 
weight of 
MABD-B in 
3.5 ml (mg) vol μL vol (μL) 
vol 
(μl) µmol 
final 
μM 
1 10 5 5 0.002 100 0.40 1.45 
2 10 3 5 0.002 111 0.67 2.42 
3 10 3 8 0.0032 152 1.07 3.87 
4 10 3 10 0.004 174 1.33 4.83 
5 10 3 11 0.0044 183 1.47 5.32 
6 10 3 12 0.0048 192 1.60 5.80 
7 10 3 13 0.0052 200 1.73 6.29 
8 10 3 14 0.0056 207 1.87 6.77 
9 10 3 15 0.006 214 2.00 7.25 
10 10 0 5 0.002 100 - - 
11 10 0 15 0.006 214 - - 
Table 2-1.  The volume and concentration of the [57Co]CoCl2 metal ion and the MABD-
PEG-biotin ligand used to determine the concentration of the ligand by isotope dilution 
analysis methodology. The highlighted row indicates the amount of CoCl2 needed to 
metallate all of the available DOTA chelator, which determined the concentration of the 
chelator. 
2.2.11  Metallation of the MABD-PEG-biotin. Four metal ions (Ca2+, Ga3+, In3+, and 
Lu3+) were used to metallate the MABD-PEG-bitoin ligand. An excess of CaCl2.6H2O 
(1.5 eq, 1.67 μmoles) was added to a reaction vessel that contained 1.13 μmoles of the 
ligand. A similar reaction protocol was used for Ga(NO3)3.6H2O. The calculated 
concentration for Ca2+ and Ga3+ metallated complexes were 1.68 and 3.93 mM, 
respectively. For Lu2O3 (67.8 mg, 170 μmoles) and In2O3 (4.8 mg, 17.3 μmoles), solid 
powders were added to the reaction vessels that contained 1.13 μmoles of the ligand and 
the reaction mixtures were stirred at 80◦C for 24 h.  The unreacted metal powders were 
removed from the reaction mixture by filtration.  The concentration for the In3+ and Lu3+ 
complexes were 1.69 and 1.96 mM, respectively. The metal ligand complexations were 
evaluated by ESI MS and are tabulated below (Table 2-2). 
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Metallated chelates 
Calculated 
molecular weight 
(g/mole) 
Observed molecular 
weight 
[M+H]+ (g/mole) 
Ca2+MABD-PEG-Biotin 1173.44 1175.01 
Ga3+MABD-PEG-Biotin 1102.4 1102.73 
Lu3+MABD-PEG-Biotin 1206.4 1208.5 
In3+MABD-PEG-Biotin 1146.37 1146.8 
Table 2-2. A list of the calculated and measured molecular weights using ESI/MS 
(Figure A 2-8 to A-2-11) of the metallated  [Ca2+, Ga3+, In3+, and Lu3+] MABD-PEG-
Biotin complexes.   
2.2.12 Selection of peptides from RPL.  A cysteine tagged random peptide library was 
constructed as described in the literature.24 The random phage display peptide library was 
constructed in Dr. George Smith’s lab using the random coding inserts indicated in the 
accompanying Figure 2-10. The phage preparation protocol to make a RPL with 1.3 x109 
primary clones can be accessed from the University of Missouri Biological Sciences 
Department website.25 Each phage from this library displays a randomized amino acid 
sequence represented by X12 (X12 stands for one of the possible 12-mer peptides shown in 
the dark background in Figure 2-10) with flanking fixed amino acids. The arginine, on 
one side of the amino acid sequence that is in close proximity to the phage, is sensitive to 
trypsin. The cysteine fixed next to the randomized amino acids bears the peptide’s 
reactive thiol. 
 
Figure 2-10. Randomized 12 amino acid sequences in the displayed peptides with signal 
peptidase and trypsin sensitive alanine and arginine in each side of flanks.  
The experiments conducted are classified into two parts: counter selection and positive 
selection of peptides from the RPL. First, to obtain a phage population that is free of 
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peptides that have affinity for Ca2+ chelates, the RPL with 1.3 x109 primary clones were 
reacted with the [Ca2+] MABD-PEG-Biotin. Second, the peptides of the RPL underwent 
counter selection to deplete the library of peptides that have affinity for streptavidin. The 
remaining library was used for positive selection using the Ga3+, In3+, or Lu3+ MABD-
PEG-Biotin selector molecules. The procedure is described below. 
(1) Into a 4-mL vial 2 mL of 3.94 x 1014 virions , 1.3 mL of 10 mM tris(carboxyethyl) 
phosphine (TCEP) and 250 µL (1.47 µmol) of Ca-MABD-biotin were added. The 
reaction was vortexed and allowed to react for 2 h at room temperature. (2) The reaction 
mixture was added to a larger vessel (50 mL) that contained 20 mL of Ca2+/Mg2+ free 
Dulbecco’s buffer. The insoluble salts precipitated and formed a pellet upon 
centrifugation. The supernatant was added to 3 mL of PEG/NaCl to isolate the phage in 
solid form by centrifugation. This step was repeated three times more by dissolving the 
pellet using the buffer solution. (3) The reaction mixture was then added to magnetized 
beads coated with streptavidin. These beads were magnetized to capture the phage that 
reacted with the Ca2+-MABD-PEG-biotin via the streptavidin biotin reaction. (4) The 
phages that did not get captured by the streptavidin beads were removed from the 
reaction mixture by centrifugation. (5) Evaluation of residual biotinylated virions were 
performed by comparing the RPL that did not react with the counter selecting 
Ca2+MABD-PEG-biotin using enzyme-linked immunosorbent assay (ELISA).  
ELISA analysis. Phage detection and quantification are accomplished by ELISA 
following standard protocols with a primary polyclonal antiphage antibody26. The general 
scheme of phage captured on a streptavidin coated plate is shown in Figure 2-11. A 
stepwise addition of anti-phage antibody (extracted from mouse serum) and anti-mouse 
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antibody to the captured phage (by virtue of the biotinylated selector molecules) results in 
a signal that is detected at 425 nm using a spectrophotometer. From the selection of 
peptides from the RPL, if specific binding is observed, the positively tested clones are 
sequenced. 
  
Figure 2-11. A schematic diagram showing the evaluation of the capurted phage using 
ELISA to detect the signal from the alkaline phosphatase upon reaction with antiphage 
antibody. The resulting signal is then used to deternine the quantity of phages that was 
captured on the tethering material.  
The phage library that was counter selected with [Ca2+]MABD-PEG-biotin was 
used for the positive selection using the three selector molecules [Ga3+, In3+, or Lu3+] -
MABD-PEG-Biotin in 3.9, 1.6 and 1.9 mM concentrations, respectively. The selection of 
peptides from the RPL was conducted using four different concentrations of the selector 
molecules (0.1, 1, 10, and 100 μM). As the selector concentration decreased a total of 12 
samples of phages were amplified and the total number virions listed in Table 2-3 
represents the selector concentration reacted and the total virions obtained after the 
selection and amplification.  
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[Ga3+]MABD-PEG-Biotin 
Selector 
conc. 100 µM 10 µM 1 µM 0.1 µM 
Total 
virions 3.99E+14 4.01E+14 3.93E+14 3.58E+14 
[In3+]MABD-PEG-Biotin 
Selector 
conc. 100 µM 10 µM 1 µM 0.1 µM 
Total 
virions 4.07E+14 4.00E+14 4.30E+14 4.01E+14 
[Lu3+]MABD-PEG-Biotin 
Selector 
conc. 100 µM 10 µM 1 µM 0.1 µM 
Total 
virions 3.99E+14 3.89E+14 3.74E+14 3.69E+14 
 
Table 2-3. The Ga3+, In3+, and Lu3+ MABD-PEG selector concentrations and the number 
of virions obtained after selection and amplification 
To evaluate the selection of peptides from the RPL, the phages that had 
undergone selection were reacted with the selector molecules once again in the presence 
of a strong Michael acceptor molecule, N-ethylmaleimide (NEM). The NEM was added 
to the samples to compete against the selectors with a weak Michael acceptor group for 
cysteine bearing peptides in the RPL. Accordingly, a graded concentration of NEM (0, 
0.006, 0.032, 0.16, 0.8, 4, 20, and 100 mM ) was mixed with 30 nM of the selector (Ga3+, 
In3+, and Lu3+ MABD-PEG-Biotin)  and the counter selector (Ca2+-MABD-PEG-Biotin) 
molecules to which the RPL solution was added to make a total of 32 samples. Each of 
these samples was evaluated using the ELISA method. In order to evaluate the amino 
acid sequenced phage binding ability to the selector metallated chelates, timed reactions 
were performed between individual phage (with known amino acid sequences) and the 
metallated selectors. Two types of plates that were coated with either streptavidin or 
neutravidin were utilized to capture biotinylated phage. The output from the third round 
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of selection, which was sequenced and amplified (12 peptides), was reacted with 
metallated chelates and poured into wells coated with streptavidin and neutravidin. The 
wells were washed vigorously as in the final round of selection, including a 1-hour biotin 
block and stripped with the strongly denaturing stripping buffer (6 M urea buffered at pH 
2.2). Wells were developed as usual for phage capture ELISA, as described earlier. In this 
manner, the percent of input virions that remained captured after washing could be 
quantified.  
2.3 Results and Discussion 
The objective of this project was to utilize the binding affinity between an 
antibody linked peptide and a metallated chelate in pretargeting.  Two derivatized DOTA 
ligands were synthesized and radiolabeled with 68Ga and 177Lu. The MABD compound, 
previously reported by Meares9, is different from the AmMABD in that the AmMABD 
has an amide terminus whereas the MABD has a carboxylic acid terminus. The synthesis 
of MABD and AmMABD, the in vitro and in vivo stability of 68Ga and 177Lu radiolabeled 
conjugates, and the biological characteristics of the small radioconjugates in comparison 
with similar hapten molecules are discussed. Also, the results from the selection of the 
peptides from RPL with affinity for the metallated chelates are described. 
2.3.1 Synthesis of MABD and AmMABD. The starting material, ABD-(t-Bu4), was used 
to synthesize the carboxylic acid and amide terminal chelators (MABD and AmMABD) 
according to  modifications adopted to convert the carboxylic acid terminus to an amide.9 
The t-butyl protected DOTA allowed for easy manipulation and purification of the 
derivatives. A similar preparation protocol for the synthesis of MABD using unprotected 
40 
 
ABD.4HCl as the starting material was reported by Meares et al.9 The result in the 
referenced study matches what is reported here, namely the 1H NMR of the protected 
MABD (t-Bu)4 and the LC/MS for the MABD. Also, the synthesis of AmMABD, which 
has not been reported before, was analyzed by LC/MS and 1H NMR. The semi-
preparative reversed-phase HPLC/MS purification of each of the deprotected chelates 
afforded pure complexes. 
2.3.2 Radiolabeling with MABD and AmMABD with 68Ga and 177Lu. The radiolabeling 
of AmMABD and MABD chelates with 68Ga and 177Lu was evaluated by TLC. 
Accordingly, the 68Ga radiolabeled MABD/AmMABD conjugate yields were 89 % and 
91%, respectively, whereas the 177Lu radiolabeled MABD/AmMABD conjugate yields 
were approximately 98% for both complexes. 
 2.3.3 Stability studies of 68Ga and 177Lu MABD and AmMABD Complexes in mouse 
serum. A radiolabeled compound is challenged in vivo by transchelating proteins; the 
thermodynamics favors the transchelation because of the overwhelming concentration 
difference between the serum proteins might and the radiolabeled chelates. Moreover, the 
fact that the chelate contains a Michael acceptor group, there is a possibility that 
nucleophilic reactive thiols on proteins compete with the selected peptides that are 
preadministered for the electrophilic carbons (weak Michael acceptor). Translating this 
outcome in vivo could mean a prolonged blood residence time for the radioconjugates, 
which would result in an obscured image and potential radiotoxicity to the blood cells. In 
the presence of 1 mM thiols in the form of mouse serum albumin, the electrophilic 
MABD and AmMABD chelates displayed no binding. This is significant since all four 
radioconjugates exhibited no binding in blood to the albumin, which contains high levels 
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of thiolates (strong nucleophiles) and suggests that these chelates should also be 
unreactive in the blood for the length of time needed for pretargeting. The results from 
serum stability studies are comparable to similar studies performed on stronger 
electrophilic radioconjugates reported by Meares.27  
The radiolabeled 68Ga MABD and 68Ga AmMABD were incubated in mouse 
serum. After 98 min of incubation, TLC analysis showed the 68Ga MABD and 
68GaAmMABD complexes maintained stability with only a low level of transchelation, 
with 94 % remaining bound (Figure 2-12). Similarly, 92 % of the 177Lu MABD and 96 % 
of the 177Lu AmMABD conjugates incubated in mouse serum remained stable. 
  
Figure 2-12. Serum stability study of the 68Ga and 177Lu AmMABD/MABD conjugates 
incubated in mice serum at 37 ◦C. The percentage of the 68Ga /177Lu associated with the 
chelates was analyzed by TLC.  
2.3.4 Hydroxyapatite (HA) challenge study. A customary way of determining the 
transchelation level of a calcium mimic radiometal that is bound to a complex is to 
incubate the radiocomplex in HA media.28-29  Adsorption of the 68Ga and 177Lu 
complexes onto HA was evaluated by incubation with HA.  The yield from the 
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incubation of 68Ga MABD and AmMABD conjugates in HA over 2 h showed 90% and 
95% remained intact, respectively. The percent intact complex from the HA challenge 
study of 177Lu conjugates showed a slightly reduced rate from 98% to 84% for 177Lu 
MABD and from 98% to 94% for 177Lu AmMABD for the time incubated (0, ¼, ½, 1, 24, 
48, 72, 96, 120, and144 h). The nominal fraction of 177Lu adsorbed onto the HA could be 
due to slow transchelation of Lu (calcium ion mimic) by HA over the incubation period 
extended for one half-life of the isotope, ~ 6 d. 
2.3.5 Biodistribution in Normal Mouse. A biodistribution study was done in normal CF-
1 mice to evaluate the small radioconjugates that exhibited high stability to serum 
challenge studies and HA with the intended use for pretargeting applications. A 
radiolabeled ligand functionalized with a weak electrophilic groups such as the MABD or 
AmMABD that remained stable in mouse serum (1 mM concentration of cysteine) is 
expected to overcome the interference from high sulfhydryl containing proteins in vivo.30   
A favorable outcome from the biodistribution profile would be that these 
radioconjugates with weak electrophilic groups do not react with random endogenous 
nucleophiles and exhibit fast blood clearance and high renal clearance without significant 
retention in any specific organs. Therefore, 68Ga and 177Lu labeled AmMABD were 
administered to normal mice. These mice were sacrificed at various time points and 
radioactivity from extracted organs were counted and evaluated  to determine whole body 
retention and clearance. The biodistribution of all of the radioconjugates exhibited low 
whole-body retention. The biodistribution of these radioconjugates are presented in 
Tables 2-4 and 2-5 for 68Ga and 177Lu-AmMABD, respectively. The results are 
expressed as injected dose per gram for the organs of interest. For both 68Ga and 177Lu-
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AmMABD, a significantly fast blood clearance was exhibited (at 15 min) and the 
majority of the activity was found in the kidneys and urine (68Ga AmMABD, 94 % and 
177Lu AmMABD 95 %) with minimal retention, which is indicative of renal clearance.  In 
addition, very little accumulation of activity was observed in the major organs (% ID of 
68Ga and 177Lu conjugates; heart 0, brain 0, spleen 0, and liver 1.1 ± 0.28, 0.2  ± 0.01) for 
either radioconjugate over 4 h and 24 h for 68Ga and 177Lu conjugates, respectively; this is 
additional evidence indicating minimal non-specific binding. 
Organs 
15 m  30 m 2 h 4 h 
% ID/g stdev % ID/g stdev % ID/g stdev % ID/g stdev 
Blood 4.65 0.85 1.35 0.47 0.00 0.04 0.00 0.08 
Heart 0.11 0.09 0.0 0.09 0.00 0.54 0.00 0.44 
Lung 1.98 0.46 0.09 0.13 0.00 0.30 0.00 0.28 
Liver 2.95 0.31 1.78 0.42 1.19 0.28 0.97 0.37 
Spleen 0.0 0.51 0.0 0.18 0.00 0.59 0.00 0.47 
Stomach 0.51 0.31 0.0 0.10 0.00 0.04 0.00 0.17 
L Int 0.51 0.15 0.09 0.06 0.59 0.64 3.78 1.12 
Sm Int 0.90 0.13 0.68 0.06 1.65 0.65 0.63 0.15 
Kidney 10.28 1.84 4.21 1.80 2.12 0.45 2.11 0.58 
Feces 0.0 0.26 0.0 75.81 0.00 1.14 0.00 2.63 
Muscle 0.0 0.03 0.0 0.09 0.00 0.33 0.00 0.09 
Bone 0.0 0.93 0.0 1.33 0.00 2.70 0.00 2.74 
Bladder 10.86 11.28 0.0 1.34 0.00 4.44 0.00 2.85 
Brain 0.0 0.11 0.0 0.05 0.00 0.14 0.00 0.12 
Pancreas 0.0 1.08 0.0 1.34 0.00 2.44 0.00 1.30 
Carcass 1.29 0.18 0.50 0.21 0.13 0.03 0.15 0.03 
Table 2-4. Biodistribution of the percent injected dose/gram of the 68GaAmMABD after 
iv injection of mice at four different time points (n=3) 
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Organ 15 m 30 m 2 h 4 h 24 h 
%ID/g STDEV %ID/g STDEV %ID/g STDEV %ID/g STDEV %ID/g STDEV 
Blood 2.58 0.21 0.69 0.05 0.03 0.03 0.11 0.17 0.00 0.00 
Heart 0.97 0.16 0.23 0.03 0.02 0.00 0.01 0.00 0.01 0.00 
Lung 1.53 0.26 0.52 0.02 0.05 0.01 0.03 0.00 0.02 0.01 
Liver 2.39 0.23 1.66 0.21 0.69 0.06 0.40 0.12 0.08 0.01 
Spleen 0.61 0.06 0.21 0.02 0.04 0.01 0.04 0.00 0.03 0.01 
Stomach 0.40 0.10 0.65 0.87 0.09 0.08 0.08 0.04 0.08 0.02 
L Int 0.45 0.09 0.12 0.01 1.15 0.20 2.31 0.63 0.19 0.11 
Sm Int 0.72 0.07 0.72 0.11 1.23 0.35 0.88 0.25 0.06 0.02 
Kidney 6.44 0.65 2.28 0.28 1.25 0.29 1.06 0.06 0.62 0.23 
Muscle 0.57 0.12 0.15 0.01 0.01 0.00 0.01 0.00 0.01 0.01 
Bone 0.51 0.06 0.21 0.06 0.07 0.03 0.06 0.02 0.10 0.02 
Bladder 12.33 6.90 2.11 1.16 0.19 0.25 0.10 0.03 0.01 0.01 
Brain 0.12 0.01 0.04 0.01 0.01 0.00 0.01 0.00 0.00 0.00 
Pancreas 0.80 0.13 0.27 0.04 0.08 0.08 0.01 0.02 -0.01 0.02 
Carcass 1.16 0.17 0.33 0.02 0.04 0.01 0.04 0.00 0.02 0.00 
Table 2-5. Biodistribution of the percent injected dose/gram of the 177LuAmMABD after 
iv injection of mice at five different time points (n=3) 
The counts from the blood fractions taken from the mice sacrificed at various time 
points were plotted versus time (Figure 2-13 (a) 68GaAmMABD and (b) 
177LuAmMABD compounds).The blood clearance shown in the graphs for both 68Ga 
AmMABD and 177Lu-AmMABD radioconjugates was fast, comparable to similar weak 
electrophilic functionalized 111In conjugates reported by Meares.27 This report also noted 
that, of the evaluated derivatized electrophilic radioconjugates, the stronger electrophilic 
radioconjugates reacted with endogenous nucleophilic molecules in vivo. The weak 
electrophilic radioconjugates, however, exhibited no significant interactions, which is in 
agreement with what was observed from the biodistribution of the 68Ga and 177Lu labeled 
AmMABD. 
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Figure 2-13. Blood clearance of (A) 68Ga AmMABD and (B) 177Lu AmMABD over 4h 
and 24 h duration, respectively. 
The stability and biodistribution of selected 68Ga radioconjugates were reported 
by Ferreira et al.31 For comparison, Table 2-6 lists selected data reported by Ferreira for 
the whole body retention and blood clearance profile of the functionalized p-Bn-NOTA 
radioconjugates along with biodistribution from 68Ga AmMABD. For 68Ga AmMABD 
the random dose retention in the various organs is slightly less than that of the 
radioconjugates with no functionalized electrophilic groups attached.  
 
 
 
 
 
 
A 
B
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Organ Ga-AmMABD 
Ga-p-NO2-Bn-
PCTA* 
Ga-p-NO2-
Bn-Oxo* 
Ga-p-NO2-Bn-
DOTA* 
Ga-p-NO2-Bn-
NOTA* 
Blood 0.00 ±0.04 11.51 2.58 4.57 0.35 
Heart 0.00 ±0.54 5.14 1.14 1.77 0.23 
Liver 1.19 ±0.30 4.52 0.96 2.86 0.63 
Spleen 0.00 ±0.59 4.11 0.90 1.20 0.00 
Kidney 2.12 ±0.45 8.49 2.52 8.06 38.10 
Muscle 0.00 ±0.33 4.38 0.60 1.14 - 
Brain 0.00 ±0.14 0.34 - 0.17 - 
 
Table 2-6. Biodistribution of 68Ga labeled radioconjugates after 2 h of post injection in 
normal mice (% ID/g, n =3). The 68Ga AmMABD complex is compared with other small 
hapten molecules labeled with 68Ga. 
* Ferreira, C. L.; Lamsa, E.; Woods, M.; Duan, Y.; Fernando, P.; Bensimon, C.; Kordos, M.; Guenther, K.; Jurek, P.; Kiefer, G. E., 
Evaluation of Bifunctional Chelates for the Development of Gallium-Based Radiopharmaceuticals. Bioconjugate Chemistry 2010, 21 
(3), 531-536. 
  A similar comparison can be made to the biodistribution analysis of the 177Lu 
AmMABD conjugate and 177Lu labeled DOTA type complexes reported by Orcutt et al.1 
The 177Lu AmMABD has a Michael acceptor group, which is more likely to react with 
endogenous nucleophiles than the hapten molecules reported by Orcutt. The 
biodistribution data of 177Lu labeled AmMABD (Table 2-5), however, is similar to what 
was reported by Orcutt for 177Lu labeled DOTA, DOTA-benzene, and DOTA-biotin 
complexes with fast blood clearance and low non-specific tissue binding. The whole 
body retention of 177Lu AmMABD is minimal (% ID remaining in the whole body was 
less than 4.5%  at 4 h and 1.3  at 24 h), which suggests a high signal-to-background ratio 
for pretargeting, an important parameter in therapy of cancer that affords minimal 
exposure to normal tissues and organs.  
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2.3.6 Selection of peptides from RPL. Phage constructs with a 12 mer peptide phage 
library were utilized to select metallated chelates (Ga3+, In3+, and Lu3+) MABD-PEG-
Biotin.    The phage displayed peptide library was comprised of 1.3 x109 individual 
clones, with 3.06 % infective units. The two important characteristics of the random 
phage display library, other than the random amino acid sequence, are all displayed 
peptides contain cysteine and have tryspsin sensitive arginine/alanine amino acid 
sequences as illustrated in Figure 2-3. 
The trypsin sensitive amino acid sequences enabled the extraction of phages that 
presumably formed strong covalent bonds with the selectors and were captured on the 
immobilizing plastic plate. For the selection process to deliver those peptides with 
affinity for the selectors, three primary components of the selector molecule needed to be 
in place. These are the metallated DOTA type chelate, the Michael acceptor functionality, 
and the biotin linkage. A molecule that lacked one of these components could interfere 
with the selection.  
2.3.7 Counter selection of peptides. This preliminary screening experiment was 
conducted to deplete the library of peptides that either directly bind streptavidin or have 
an affinity for [Ca2+]MABD-PEG-Biotin. As a result of the counter selection process, 
1:1000 of the phage library were found to either directly react with the streptavidin or the 
Ca2+MABD-PEG-Biotin (biotinylated peptides in such reaction would then be captured 
by streptavidin) and removed. A follow up analysis of the counter selected phage 
peptides resulted in 67 % or 6.49 x 1013 virions/mL recovered from the RPL. These 
recovered phage virions were used for the positive selection of peptides using the three 
metallated selectors. 
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2.3.8 Selection of peptides with the metallated selectors (Ga3+,In3, and Lu3+ MABD-
PEG-Biotin). The preliminary selection experiments showed varying levels of response 
to the selector molecules during the evaluation. The phage selected for affinity against 
Ga3+ chelates with a concentration of 10 μM and 1 μM exhibited high absorption signal 
with no response to the competing NEM compound at all concentrations of NEM. The 
phage selected at lower concentrations of Ga chelates (100 nM and 1 nM) however, 
showed a decreasing signal with increasing concentration of the NEM. Phages selected 
for Ga3+, In3+ or Lu3+ chelates were also reacted with Ca2+ chelates. In some instances the 
results showed  phage tested in the presence of Ca2+ chelates were similar to the 
metallated chelates (Ga3+, In3+, or Lu3+ MABD-PEG-Biotin) they were selected against. 
This led to an investigation of the amino acid sequence of the peptides displayed on the 
phage that gave signals at higher concentrations of NEM. The phage that were harvested 
were considered strong binders to the metallated chelates since they stood up to the 
competition of the high concentrations of NEM and they responded to the trypsin 
cleavage, indicative of phage capture via the P3 displayed peptides from the selection, 
and not a random binding by virtue of the outer protein coat. 
The amplification of phage was narrowed down to phages selected against low 
concentrations of selector chelates (10 nM Ga3+ and Lu3+-MABD-PEG-Biotin and 100 
nM of In3+-MABD-PEG-Biotin) and reacted in the presence of high concentrations of 
NEM up to 66.7 mM). The captured phage were released by adding the enzyme trypsin to 
the plastic wells. The released phage comprised the output of selection. Those output 
virions were used to infect fresh E. coli host cells, which were cultured overnight in 
growth medium. The output phages thus increased in numbers by a factor of a million or 
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more. The DNA nucleotide bases of the amplified clones were sequenced and the amino 
acid sequences were identified (Table 2-7).  
Name of clone Displayed peptide sequence Ga In Lu 
DOTA01 adgacTFQRGTHPQFETaagarr 6    54 
DOTA02 adgacSFVCWSGHPQNSaagarr 22 17  21 
DOTA03 adgacMRCMAWGGYHPQaagarr 8 7  13 
DOTA04 adgacFSHYSWGGDHPMaagarr 18      
DOTA05 adgacHFSQPHPQFEQPaagarr       18 
DOTA06 adgacFYPVSDRHPQAGaagarr 5     5 
DOTA07 adgacPWAFSHPQFETEaagarr 8       
DOTA08 adgacGAGIGNYYNLGLaagarr       8 
DOTA09 adgacFWSFDPDFVKMTaagarr 2  4    
DOTA10 adgacAWTGWHPQGDLPaagarr 6       
DOTA11 adgacFLCVSRPDEFSSaagarr    4    
DOTA12 adgacGRAWHPQFGPPLaagarr 1     3 
DOTA13 adgacSWGKTWGGRHPMaagarr 2       
DOTA14 adgacIWRWRLEPYDLRaagarr 1       
DOTA15 adgacLWEGFPWGGYCKaagarr 1       
DOTA16 adgacAWGSLDRYSWQWaagarr 1       
DOTA17 adgacWQFRYYQIGSYKaagarr 1       
DOTA18 adgacPWTLWTFIEGVSaagarr       1 
DOTA19 adgacSHLDDSQLTPETaagarr    1    
DOTA20 adgacCAWGGFHPQGPGaagarr 1       
DOTA21 adgacAWGSHRHPMSPLaagarr 1       
DOTA22 adgacCYYVVGHPQGDPaagarr 1       
DOTA23 adgacVFNKTCNHPQFEaagarr 1       
DOTA24 adgacWFCGHPQFQNPPaagarr 1       
DOTA25 adgacSSWCYLIYDHPQaagarr         
DOTA26 adgacVECFFMDHPQNMaagarr       1 
DOTA27 adgacFIGHPQFAGYGWaagarr       1 
IV1 adgaRGGRCLLCCLCLWWAgaag 36 37   
IV2 adgaAVAGGRSVVDARVARgaag    54   
Table 2-7. The amino acid sequences from the selected phage are listed along with their 
frequency of appearances. The amino acid sequences in the randomized positions are 
printed in capital letters; other amino acids are printed in lower-case letters.  Cysteine (C) 
are printed in red letters.  A streptavidin-binding motif HPQ or HPM (histidine, proline, 
and gluthamine or methionine) observed in most of the peptides is printed in blue letters.  
The 9 peptides that do not have this motif are highlighted in yellow. A distribution of 
sequenced phages among three selector chelates is shown. 
The presence of HPQ (histidine, proline, and glutamine) or HPM (histidine, 
proline, and methionine) motifs suggest that most of the peptides were selected by virtue 
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of their ability to bind directly to the immobilized streptavidin, rather than by virtue of 
their ability to couple to the selector. It was a surprise that the streptavidin-binding 
peptides emerged from the selections in spite of the strong measures taken (counter 
selection to avoid Ca2+ chelates or streptavidin binding peptides, phage precipitation to 
discard random binding of peptides during phage the positive selection, and applied 
strong wash media multiple times). A few of the selected peptides, highlighted in yellow, 
do not have the streptavidin-binding motif; they perhaps are the best prospects for being 
the desired peptides. 
The signal from the ELISA reading showed that all the phage on the streptavidin 
coated plates had varying levels of signal whereas similar reaction mixtures reacted with 
the NA coated plates presented minimal signal. Figure 2-14 shows two batches of 
selector metallated chelates (Ga3+, In3+, and Lu3+) and the counter-selector Ca chelates 
(biotin is the control) and the selected and sequenced phage. 
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Figure 2-14. Peptides with known amino acid sequences reacted with  selector chelates 
and the control (Ca2+ chelates and boitin). A magic peptide that was biotinylated by 
coupling to the counter-selector or the selector would be captured by both streptavidin 
and neutravidin. Second, the virions were captured by streptavidin even in the control 
wells where no selector was present, indicating that they were captured directly rather 
than because they coupled to the selector.  
The alternative to eliminate the possibility of direct interaction between phage and the 
streptavidin is to use neutravidin, a deglycosylated protein capable of binding biotin with 
a high association rate  [ka = 1015]32 and minimal nonspecific adsorption. A repeat of the 
experiment that produced the sequenced peptide in Table 2-7 was conducted using 
neutravidin coated plastic plates coated, instead of streptavidin. The final round of 
selection was repeated using three selector molecules ([Ga3+, In3+, and Lu3+]-MABD-
PEG-Biotin) with graded concentrations of the NEM competitor. The selection resulted 
in 48 amplified outputs, 16 each for the ([Ga3+, In3+, and Lu3+]MABD-PEG-Biotin 
selectors, (rather than individual phage clones). The evaluation from this experiment 
showed only one of the output captured significantly above background. The percent of 
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input virions captured from this output population was quite high (1-4 percent). 
Evidently, this output population was subsequently shown to be dominated by a single 
clone displaying the peptide adgacWAWWTYDIKGCMaagarr, which presumably is 
responsible for the population’s neutravidin-binding activity. Figure 2-15 shows the 
performance of the virions selected for the metallated chelates and tested against the 
same chelates plus biotin and Ca2+ chelates. This specific clone did not show any 
response when it was tested against the different metal ion (Ga3+, In3+, or Lu3+) 
complexes. Although multiple attempts were made to find a peptide that has an excellent 
conformation, there is no indication that the output population includes virions displaying 
effective peptides.  
 
Figure 2-15. The 48 phage clones amplified to react with the three metallated chelates, 
selectors ([Ga3+, In3+, and Lu3+]MABD-PEG-Biotin) and  samples that are considered as 
blanks such as the Ca2+ chelates and a biotin that is not linked to a DOTA chelator. The 
ELISA analysis of this samples showed one of the 48 phage clones presented a new 
amino acid sequence that directly interacts with the plastic plate coated with neutravidin. 
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2.4 Conclusion 
 For a radioconjugate to be considered in pretargeting, it needs to demonstrate a 
high affinity for its cognate peptide, a high stability in vivo, and a favorable 
pharmacokinetic profile, all of which ensures fast blood clearance and excretion through 
the kidneys without any significant retention by any organs. Based on the results obtained 
in this study, serum stability studies indicate the Michael acceptor groups are not 
susceptible to nucleophilic attack in the presence of thiols. This could be due to the weak 
Michael acceptor group that is less likely to react with free sulfhydryl as opposed to the 
strong Michael acceptor groups, which are more reactive in similar incubation media. 
Similarly, the biodistribution profiles of 68Ga3+ and 177Lu3+ AmMABD indicates minimal 
non-specific binding and fast blood clearance, which is consistent with the biodistribution 
profiles of 111In3+ labeled EDTA ligands functionalized with a Michael acceptor group.27 
The selection of peptides with affinity for the metallated chelates did not yield the amino 
acid sequences that we anticipated. The presence of contaminant peptides that 
overwhelmed the final positively selected library have effectively diminished the chances 
of finding the desired sequence during the intermediate steps of phage amplifications. 
Although, the selection process has attempted from the start to eliminate such 
possibilities by conducting counter selections, the contaminant HPQ motifs were resistant 
in the unfavorable reaction media for random binding.  This study has developed 68Ga3+ 
and 177Lu3+ AmMABD radioconjugates with favorable characteristics with both in vivo 
and in vitro stabilities for potential pretargeting applications. 
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2.5 Future Studies 
The selection strategy developed in this project could serve to select strong 
radioconjugate binding peptides, with the appropriate changes in the design of the library 
and the structure of the selectors. In particular, the trypsin-release vector developed in 
this project is highly applicable to any selection for irreversible covalent coupling rather 
than reversible non-covalent binding. The obvious modification that would be made for 
further selection of peptides from the RPL would be to use neutravidin coated capturing 
plates instead of streptavidin. Although, the study showed there could be some amino 
acid sequences that directly bind the capturing plate, those virions clones can easily be 
eliminated during counter selection. There is a high possibility for the counter selection to 
eliminate these unwanted clones because the neutravidin is a deglycosylated compound 
and discourages random binding of peptides, such as one displayed on phage.  
Other changes that could enhance the affinity selection are increasing the 
concentrations of the selector molecules. This study used 100 nM selector concentrations 
and the future study should consider 50-100 μM concentrations of the metallated chelate 
to encourage the reactivity between the peptide and the selector chelates. Although, the 
selection stringency could suffer from the increase in the concentration of the selector 
molecule, it could still benefit from the fact that the selector has a weak reactive group, 
which requires an excellent conformation of the peptide to form covalent binding. In 
addition, the stipulated concentration of the selector chelates can still be accommodated 
by the binding sites of the capturing neutravidin coated plates.  
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Figure A 2-3. The LC/MS on C-18 reversed phase column analysis of the MABD   
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  Figure A 2-4. The LC/MS on C-18 reversed phase column analysis of the AmMABD  
 
[M+H]+ 
[M+K]+ 
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Figure A 2-7. C-18 reversed phase HPLC- ESI-MS analysis of the purified MABD-PEG-
Biotin 
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Figure A 2-8. ESI/MS Ca2+MABD-PEG-Biotin 
 
Figure A 2-9. ESI/MS Ga3+MABD-PEG-Biotin 
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Figure A 2-10.  ESI/MS Lu3+MABD-PEG-Biotin 
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Figure A 2-11.  ESI/MS In3+MABD-PEG-Biotin 
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Chapter 3  
Separation and purification of no carrier added 161Tb, 166Ho, and 177Lu 
by column chromatography 
Introduction 
The radiolanthanides have extensively been evaluated in nuclear medicine for 
potential targeted radiotherapy. The radiolanthanides are useful in treating rheumatoid 
arthritis, which is mainly localized in the synovium.1 The aim of radiation synovectomy 
is to reduce pain, improve mobility, and preserve joint function.1  Hydroxyapatite (HA) 
[Ca10(PO4)6(OH)2] is  a major chemical constituent of skeletal bone matrix. The similar 
chemical properties between the lanthanides and Ca2+ ions prompted the development of 
radiopharmaceuticals that use radiolabeled HA as a vector to deliver the radiation dose to 
the target.  Radiolanthanides (177Lu and 153Sm) are frequently used to label HA 
particulates for synovectomy radiation. The radioisotopes that are utilized for therapy are 
also incorporated in bifunctional chelating systems to target biological receptor sites. 
Radiolanthanides are frequently used in receptor-based radiopharmaceuticals that require 
high specific activity or no-carrier added (nca) radiolanthanides. Specific activity (SA) is 
calculated as the activity of the radioisotope per given mass (Ci/mg). To maximize the 
specific activity, the amount of the non-radioactive mass has to be reduced or eliminated 
to obtain a no-carrier-added radioisotope. Most of the reactor produced radiolanthanides 
have low specific activity since the irradiated targets are of the same element as the 
produced radionuclide. Table 3-1 illustrates the nuclear properties of 161Tb, 166Ho, and 
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177Lu and the specific activities, both theoretical and currently achievable. An example 
for calculating the  theoretical specific activity of 177Lu is indicated in Equation 3-1. 
Radio- 
nuclide 
Target 
Radio- 
nuclide 
Decay 
mode T1/2 (h) 
Emax β-,
MeV  
γ energy, 
keV  
(% abundance)
Theoreti
cal 
Specific 
Activity 
(Ci/mg)
Achievable 
Specific 
Activity 
(Ci/mg) 
Mean* 
tissue 
range 
(cm) 
177Lu 176Yb β−, γ 161 0.5 208  (11) 110 25‡  0.24 
166
Ho  164Dy β−, γ 26.8 1.86 80.6 (6.2) 704 2.2‡  1.39 
161Tb 160Gd β−, γ 165.8 0.59 
48.9 (17) 
74.6 (10) 117 105
† 
 0.2 
Table 3-1. The nuclear properties and decay characteristics of the radiolanthanides. The 
achievable specific activities for 177Lu and 166Ho are obtained after the direct production 
of each of the radionuclides, while the 161Tb SA is achieved using the indirect nuclear 
reaction. The symbols *, ‡ and † denote referenced values2-4.  
  Ci/mg  111  
 g)  1mg/  (1000* dps/Ci)  x10(3.7* 3600  36159 94176
  x1002262 
 110001disint.(s)10 x (3.7* (sec) life-(half *) (g/mole) mass ((atomic
 atoms/mole 10 x 6.022 *  ln(2)  
life)-lf((ln(2)/ha * atoms) ofN(number  A     
(mg)  
(Ci)A   
massunit 
(s) tionsdisintigra   activity  
10
23
1- atoms10
23
-1
 177





)hsec/)(h.(*)mole/g.((
.*)ln(
)g/mg/g(*))Ci/(
massunit
Specific Lu

 
Equation 3-1. Calculation of the theoretical specific activity  
  
Production of 177Lu. Lutetium-177 is the most widely investigated radiolanthanide for 
potential radiotherapy applications, especially in receptor mediated peptides such as 
octreotate (analogue of somatostatin (SSTR(2)). In addition, a radioconjuate linked to 
Bombesin, a GRP (gastrin releasing peptides)receptor targeting peptide, is used for 
treatment of a variety of human cancer cell lines including prostate.5-6  Although, there 
are numerous publications that indicate the superiority of 177Lu labeled over 90Y 
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bioconjugates (90Y is a radioisotope approved by the Food and Drugs Administration 
(FDA))7 due to its favorable nuclear properties for therapeutic treatment (lower mean 
energy of the β- particles and therefore shorter range, which is preferred for therapy of 
small tumors). However, 177Lu has not been approved for radiopharmaceutical 
applications in the US, although 177Lu-DOTA-TATE has been approved in some parts of 
the world (Warsaw, Poland)8 for radiotherapeutic treatment of patients with disseminated 
neuroendocrine tumors. 
 The nuclear reaction that has been frequently used to obtain 177Lu is the direct irradiation 
of an enriched 176Lu target. Because of the rather large cross section of 176Lu (σ = 2,300 
barns), 177Lu can be produced directly with relatively high specific activity at nuclear 
reactors via the (n,γ) production route. However, during irradiation of the 176Lu target, the 
long-lived isomer 177mLu (T1/2 = 160.1 d) is also produced  
176Lu (n,γ)177Lu 
176Lu (n,γ)177mLu 
An alternative production route that involves neutron irradiation of an enriched 
176Yb target results in an indirect production of no-carrier 177Lu (Table A 3-1). This 
approach, however, requires chemical separation of the177Lu from the Yb target (Figure 
3-1).  
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Figure 3-1. Indirect production 177Lu from neutron capture of enriched 176Yb.  
Production of 166Ho from an enriched Dy target. 166Ho-DTPA has been proposed as a 
potential liquid source for filling balloons for endovascular brachytherapy by Hong et al.9 
This report indicated ethylenedicysteine compounds were filled with 166Ho-DTPA 
solutions and used as an alternative therapeutic agent to that of 188Re labeled therapeutic 
agents for artherosclerotic coronary artery.  
The no-carried-added 166Ho production route involves a double netron capture on 
an enriched164Dy target to produce the intermediate 166Dy, which then β- decays to 166Ho. 
The isolation of 166Ho, as shown in Figure 3-2, requires multistep separation to avoid 
accumulation of 165Ho (stable) from the decay of 165Dy. The enriched 164Dy has a high 
cross section that proceeds through a single neutron capture to produce 165Dy.10  The 
objective of the first separation is to isolate the Dy fraction from the Ho. This is because 
the accumulation of the 165Ho from the β- decay of 165Dy results in a neutron capture on 
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165Ho to produce the long-lived 166mHo impurity (t1/2 = 1,200 y). The calculated decay 
time to allow the growth of 166Dy is 48 h before performing the separation of 166Dy from 
166Ho.  
 
Figure 3-2. 166Ho production scheme 
Production of 161Tb. The nuclear properties of 161Tb are similar to those of 177Lu, 
especially its half-life (6.90 d) and relatively low mean β- energy. The production of 
161Tb involves neutron irradiation of an enriched 160Gd target as shown in Figure 3-3. 
This nuclear reaction yields the 161Gd intermediate, which β- decays to 161Tb.  Because of 
the low cross section (1.5 b) of the target 160Gd,  it requires high quantities of enriched 
161Gd target to obtain sufficiently high activity of 161Tb.4 
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Figure 3-3. 161Tb production scheme  
Chemistry of the Lanthanides: The common features in the lanthanide series include (1) 
Ln ions are stable in their +3 oxidation state (especially, in aqueous media), (2) they form 
labile ionic complexes, (3) insoluble hydroxides precipitate at neutral pH unless 
complexing agents are present, and (4) a decrease in radii of the lanthanide ions across 
the series from La to Lu. The last characteristic is the result of the slight spatial extension 
of the 4f valence orbitals by the addition of valence electrons that cannot effectively 
shield the increasing nuclear charge as the atomic number increases across the series. 
This phenomenon causes shrinkage in the atomic and ionic radius, which is commonly 
referred as the lanthanide contraction.11 The Ln3+ metal ligand coordination depends on 
the electronegativity of the coordinating atom with the order of affinity for the Ln3+ ions 
O>N>S.  Lanthanide ions have large ionic radii, and are typically hard Lewis acids. 
Because of ligand bonding with the lanthanide metal ions is electrostatic in nature, the 
74 
 
coordination geometries of lanthanide ions are governed by the steric requirements for 
the ligand, minimizing ligand-ligand and metal ligand repulsions.11-12  
Separation of Lanthanides. The general separation scheme to produce high specific 
activity lanthanides is divided into three types: 1) chemical separations, 2) ion-exchange 
methods, and 3) extraction column chromatography.1) Chemical separations rely on 
using the difference in oxidation states between the separating lanthanides ions. For 
instance, Sm2+, Eu2+, or Yb2+ ions are obtained by reducing the +3 oxidation state of the 
metal ions and can subsequently be isolated from the reaction mixture in the solid state by 
adding precipitating agents. This multistep separation process is further elaborated in the 
next chapter. (2) Due to the similarities of the the ionic radii of the individual Ln3+ ions, 
there are not significant differences in their affinities for polystyrene-based cation 
exchangers. Researchers, therefore, have linked the unsuccessful ion exchange separation 
process of lanthanide elements using mineral acids (HCl, HBr, HNO3 and H2SO4) to the 
close chemical properties that exist in the lanthanide series13-14. However, Ln3+ 
complexing agents, which are used as eluents, complex quickly with the rare earth 
elements with different stability constants for the various lanthanide ions.15 The 
complexing agents respond to the acidity and ionic strength of the solution and to the 
presence of metal ions. The strong binding complexing agents such as EDTA and DTPA 
are effective in chelating lanthanide ions. EDTA is readily available, inexpensive, and 
easy to regenerate. However, due to EDTA’s low solubility, elutions cannot be conducted 
in acidic environments (pH <3).16  
Various complexing agents and ion exchange chromatography media have been 
evaluated to separate the lanthanides.17 Chopin et al investigated the separation factors of 
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the radiolanthanides using ion exchange chromatography and complexing agents such as 
glycolic acid, lactic acid, and alpha-hydroxyisobutyric acid (α HIBA). These complexing 
agents have high affinities for the Ln3+ ions (loaded on a cation exchange column), and 
an increase in the formation constant from left to right across the lanthanide series 
(complexes most strongly with the smallest Lu3+) provides a convenient method for the 
chromatographic separation of these ions. Based on these reports, the Ln3+ ions were 
effectively separated with the highest separation factor using α-HIBA.  (3) Another 
separation method takes advantage of the affinity of the Ln3+ for phosphonate groups, 
namely extraction column chromatography (ECC) with organophosphonic acid groups 
adsorbed onto acrylic ester resins, which are commercially produced and sold by 
Eichrom LLC as Ln resins. The work reported by Horwitz et al. discussed the separation 
of 177Lu3+ from Yb3+ using Ln resin.18-19 Currently, there are a series of Ln resins 
commercially available with differences in their chemical structures (Figure 3-4 ). A 
report by Mirzadeh et al. showed the separation of 177Lu from the Yb target using the Ln 
resin. The separation conditions involved high concentrations of the hydrochloride acid 
to separately elute the two elements. Since the HDEHP, compared to the HEHEHP (Ln2) 
is quiet a strong acid that it needed large amount of the eluting solvent to protonate the 
phosphonate active groups on the resin. The elution profile from the Yb/Lu separation 
using the Ln resin is referenced in Figure A 3-8.20In this study the Ln2 resin was 
prefered to the Ln resin because of its weaker acid that requires less concentrated acidic 
eluents to push the retained the analytes of the column.  Accordingly, the separation of 
the radiolanthides, 177Lu3+, 166Ho3+, and 161Tb3+ is called the Ln2 resin. 
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Figure 3-4. The organophosphorous groups adsorbed on the resin Ln (bis(2-ethylhexyl) 
hydrogen phosphate (HDEHP)) and Ln2 (2-ethylhexyl hydrogen (3-
ethylheptyl)phosphonate (HEH (EHP)) resins. 
 
Various reports have utilized one of the separation methods (ion exchange 
chromatography or extraction chromatography media) to achieve high SA 
radiolanthanides (177Lu, 166Ho, and 161Tb). Knapp et al. investigated two types of 
chromatography media in an attempt to separate 166Ho from Dy targets.21 The first 
method was separation by paper electrophoresis using α-HIBA as the complexing agent 
and a cation exchange resin as the stationary phase. The second separation method 
evaluated was extraction chromatography, using glass powders that were pre-impregnated 
with di-(2-ethylhexyl) phosphoric acid (HDEHP). This separation, also referred as 
partition chromatography, and which is similar to extraction column chromatography, 
took advantage of the different formation constants of the Ln3+ and the ligands 
(phosphonates) to elute Dy3+ first and Ho3+ second.  The loaded sample (166Dy/166Ho) was 
eluted using HNO3 solution. Unlike the cation exchange resins, the stationary phases are 
usually custom prepared using glass powders or silica impregnated with HDEHP or 
77 
 
tributylphosphate (TPB). In their report a better elution profile with slight shoulder 
broadening was attained with TPB as the stationary phase and elution with a high 
concentration of HNO3 (13 M). The second best elution profile was obtained using 
HDEHP as the stationary phase and eluting with 1.6 M HNO3. The authors acknowledged 
the disadvantage of using high acid concentrations and recommended HPLC assisted 
column chromatography. 
Ramaswami et al. alludes to the process of separation of radioactive 
157/158Ho/157Dy products obtained by irradiating enriched Eu isotopes.22 This report 
established that complexation between HDEHP and the Ln3+ increases with decreasing 
ionic radii of Ln3+.  
The objective of the current study was to evaluate the performance of extraction 
column chromatography media that uses the organophosphoric acid active groups 
adsorbed on a resin in separating 177Lu, 166Ho, and 161Tb from their corresponding 
enriched targets. A comparison between previously reported separation techniques and 
the current study is made to determine the efficiency and reproducibility of extraction 
column chromatography. 
3.2 Experimental 
3.2.1 Chemical and reagents. Ytterbium oxide (99.998 % purity), gadolinium oxide 
(99.99%), and holmium oxide (99.99%) were purchased from Alpha Aesar (Ward Hill, 
MA). Optima grade quality hydrochloric and nitric acid were purchased from Fisher 
Scientific (Fairton, New Jersey). Deionized water using a Milli-Q system was18 Ω cm-1.  
78 
 
Radiochemical preparations. A high purity germanium (HPGe) semi-conductor γ-
detector was utilized for counting the radioactive samples and fractions. The gamma peak 
with the highest decay abundance was used to follow the separations for each 
radionucldie. Yb/Lu (γ-energy intensity for 177Lu and 175Yb is 208 keV and 396 keV, 
respectively); Dy/Ho (γ-energy intensity for 166Dy and 166Ho is 82.4 keV and 80.5 keV); 
and Gd/Tb (γ-energy intensity for 159Dy and 161Tb is 75 keV and 365 keV). The γ- decay 
counts were computed and reported as activity (Genie software 2000). 
        A typical isotopically enriched target (160Gd, 164Dy, and 176Yb) for irradiation 
contained 1-2 mg of Gd2O3, Tb2O3, or Yb2O3 (Figure A 3-1). The targets were initially 
converted to the LnNO3 form by dissolving Ln2O3 in dilute nitric acid (0.3 M), followed 
by evaporation to dryness in quartz vials. The quartz vials containing the enriched targets 
[(160Gd, 164Dy, or 176Yb) NO3] were irradiated at the University of Missouri Research 
Reactor Center (MURR). In general two target irradiation positions were used (thermal 
neutron flux trap and reflector). The thermal neutron flux trap was 3 x 1014 neutrons 
/cm2s and the irradiation time for this position is normally 155 h. The flux in the reflector 
position was in the range of 1 x 1013 to 1 x 14 neutrons /cm2/sec and the irradiation time 
last only for 3-4 days. Following irradiation, the samples were dissolved in 500 μL of 
0.05 M HCl and mixed with 30-50 mg of their corresponding non-radioactive LnNO3 (Ln 
= Gd3+, Dy3+, or Lu3+).  
3.2.2 Preparation of chromatography columns. The extraction column chromatography 
Ln2 resin with the (2-ethyl-1-hexyl) phosphonic acid mono (2-ethyl-1-hexyl) ester 
(HEH[EHP]) reactive group adsorbed on an acrylic ester polymer support (45 μm mesh 
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size) was acquired from Eichrom Technologies LLC (Lisle, IL). The mobile phases were 
prepared by diluting optima grade nitric acid. 
A water jacketed glass column (to maintain temperature) with internal threaded 
ends for a screw-cap fittings  (dimension 11 ID x 300 mm, 29 mL capacity volume) from 
Sigma-Aldrich (St. Louis, MO; ACE glass manufacturer) was packed with a slurry of 
Ln2 (0.1 M HNO3 is used to make the slurry) resin to a bed volume of 20 mL. The slurry 
of the Ln2 resin was degassed prior to packing the column to remove air bubbles. The 
resin slurry was gently added to the column to the desired 20 mL bed volume with the top 
of the resin covered with a polyethylene frit. After allowing the resin to settle by gravity, 
the top end of the column was capped and external pressure using nitrogen gas was 
applied to pack the loose particles with 0.05 M HNO3. The mobile phases were filtered 
using 0.45 μm Millipore filters and degassed at room temperature.  For trials that have 
the heat exchange column conditioned at 50 ◦C, however, the mobile phases were 
degassed at 50 ◦C. 
The column was equilibrated with 0.1 M HNO3 (3 bed volumes, 60 mL). The 
sample (175Yb/177Lu) was loaded onto the column in ~ 10 mL. The first elution was made 
using 1.5 M of HNO3 in 200 mL followed by 30 mL of 4 M HNO3, which removed the 
remaining 177Lu that was retained on the column. The flow rates were evaluated at 2, 3, 4, 
and 5 mL/min. 
3.2.3 Separation of 177Lu from Yb targets. The sample preparation for the separation of 
the bulk amount of Yb from Lu involves dissolving a weighed amount of Yb2O3  (35-45 
mg, 0.09 -0.1 mmole) to obtain the Yb(NO3)3. The use of Yb2O3 as a source of Yb is 
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required to accurately determine the mass of Yb, as hydrated YbCl3 or NO3- are 
hygroscopic  and that adds mass that would be difficult to quantify. These samples were 
then spiked with 500 μL of 175Yb/177Lu (~1 mCi) and ~ 9 mL of milli Q water were 
added to make the final volume 10 mL.  The sample was loaded onto an equilibrated Ln2 
column using a 20 mL syringe.  
3.2.4 Separation of 166Ho from Dy targets. The irradiated sample was dissolved in 5 mL 
of 0.05 M HNO3 and loaded on to a column containing the Ln2 resin (11 X 200 mm). 
The first 100 mL fraction eluted with 0.5 M HNO3 (fraction 1-10) contained 3.95 % of 
the 166Dy. The next 60 mL of collected fractions (fractions 11-17) contained the 
remaining 94 % of the 166Dy. The 166Ho started to elute in fraction 21, and fractions 20-23 
containing only 166Ho (free of 166Dy) were eluted with 30 mL of 3 M HNO3, which 
contained 97 % of the total 166Ho in the sample. 
3.2.5 Separation of 161Tb from Gd targets. The 161Tb was obtained after irradiation of the 
enriched 160Gd that has small amounts of 158Gd contaminant, which undergo a neutron 
capture to produce 159Gd. The high abundance gamma rays of 159Gd (363.6 keV) and 
161Tb (74.6 keV) were used to track the Gd and Tb fractions, respectively.  Non-
radioactive Gd2O3 (46 mg, 0.867 of natGd) was dissolved in 500 μL of 3 M HNO3 and 
H2O2 (30 %).  This sample was diluted in 10 mL of Milli Q water and spiked with 
159/161Gd/161Tb activity. The Ln2 column was equilibrated with 0.05 M HNO3 and the 
sample was loaded. The selective elution of Gd followed by Tb was conducted by 
loading 0.15 M HNO3 in 200 mL, followed by subsequent addition of 3 M HNO3.    
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3.3 Results and Discussion 
3.3.1 Separation of 177Lu from Yb targets. The separation of the neutron irradiated 
enriched 176Yb from the 177Lu was performed to remove the bulk of the Yb target 
material. The separation using extraction column chromatography resulted in removing 
the excess Yb from the 177Lu using acidic media as the mobile phase. The separation 
conditions to obtain a better resolution of the separating peaks such as the concentration 
of the mobile phase and the flow rates were evaluated and are discussed below.  
The influence of eluent concentration. A successful sequential elution of Ln3+ on an 
extraction column chromatography can be obtained with optimal acid concentrations. An 
increase of the acid concentration results in the release of the metal ions. Although, it 
takes high concentrations of HNO3 to cause the protonation of the phosphonates, the 
concentration used for selectively eluting the metal ions on the Ln2 resin was less than 
what was reported for obtaining similar outcomes (in separating 177Lu from Yb targets) 
using the Ln resin.20 Conversely, a dilute concentration of the acid does not have the 
strength to elute the Ln3+, but rather increases the column elution time. The optimum acid 
concentration for the separation of the Yb from the Lu on the Ln2 column was 1.5 M 
HNO3 and resulted in eluting the 175Yb first followed by 80-85 % of  177Lu , while only 
15-20 % of 177Lu was lost to the Yb fraction. The differences in the percent loss of 177Lu 
were due to change in flow rates, which is discussed below. 
Influence of flow rate on the separations. The flow rate was investigated to determine 
the optimum conditions that afforded a better separation profile. Flow rates ranging from 
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2-5 mL/min were evaluated while all other parameters were kept the same. There was not 
a discernible difference observed in the shape of the two separating peaks at the different 
flow rates evaluated except at 5 mL/min. As the flow rate increased, the amount of 177Lu 
lost in the Yb fraction increased. Table 3-2 summarizes the different flow rates that 
brought about an increase in the percentage loss of 177Lu in the Yb fraction, which 
increased from 14 to 26 % with increasing flow rates from 2 to 5 mL/min. 
Amount of 
Carrier 
Yb2O3 (mg) 
Flow rate 
(mL/min) 
Volume of 
fractions 
containing 
175/176Yb (mL) 
% Loss of  
177Lu in the 
Yb fraction 
Volume of 
fractions 
containing 
only 177Lu 
(mL) 
Number 
of trials 
45 2 120 ± 10 14 70 ± 0 2 
45 3 115 ± 20  18.3 ± 4 80 ± 20 3 
45 4 115 ± 10 18.5 ± 2 40 ±10 2 
45 5 120  26      100  1 
Table 3-2.  Summary of Yb/177Lu separation profile at various flow rates 
 As a result of the short reaction time between the extracting organophosphorous group 
and the lanthanides, the gap between the separating peaks becomes narrower and overlap 
occurs at 5 mL/min. Of the four flow rates evaluated, the majority of the 177Lu was eluted 
in 50 mL of solvent containing a mixture of 1.5 M and 4 M HNO3. Since the solvent flow 
rate was driven by a positive pressure, the bed volume of the column was slightly 
compressed with increasing pressure to generate a flow rate of 5 mL/min. This resulted in 
broadening of the Yb peak, which then overlapped with the Lu peak. A representative 
chromatography distribution profile of Yb/177Lu using Ln2 resin at 4 mL/min is shown in 
Figure 3-5. Additional chromatography profiles of Yb/177Lu at different flow rates are 
shown in the Appendix (Figures A 3-2 to A 3-5).  
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Figure 3-5. Separation of 177Lu from the Yb targets.Ytterbium oxide (~ 45 mg) digested 
in 3M HNO3 was spiked with  175Yb/177Lu and diluted to 10 mL in milli Q water. The 
sample was loaded onto a column pre-equilibrated with 0.5 MHNO3 at 50 ◦C. The two 
radioisotopes were eluted using initially 1.5 M HNO3 in 180 mL to elute the Yb, 
followed by 4M HNO3 to elute the 177Lu at a flow rate of 4 mL/min. 
3.3.2 Separation of 166Ho from Dy targets. The irradiated enriched Dy2O3 target was 
separated from the desired radioisotope 166Ho using the Ln2 resin. The first 100 mL of 
the fraction eluted with 0.5 M HNO3 (fractions 1-10, each containing 10 mL) contained 
3.95 % of the 166Dy. The next 60 mL collected (fractions 11-17) contained the remaining 
94 % of the 166Dy. The 166Ho started to elute in fraction 21, and fractions  20-23 
containing only 166Ho (free of 166Dy) were eluted with 30 mL of 3 M HNO3, which 
contained 97 % of the total 166Ho in the sample. The elution profile for the separation of 
Dy/Ho is shown in Figure 3-6.  
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Figure 3-6. Separation of 166Ho from the Dy target using the Ln2 resin. The Ln2 
column was equilibrated with 0.15 M HNO3. The Dy2O3 (Dy = 5 mg) sample was 
spiked with 166Dy/166Ho and diluted with milli Q water to a final volume of 10 mL. 
Intially 200 mL of 0.5 M HNO3 was added at 4 mL/min to the column (temperature 
maintained at 50 ◦C) followed by 50 mL of 3 M HNO3 to elute the 166Ho.  
3.3.3 Separation of 161Tb from Gd targets. Separation of 161Tb from the Gd target was 
successfully performed using the Ln2 resin (Figure 3-7). The eluting conditions for 
fraction containing the 161Tb target were 0.5 M HNO3, which in comparison with mobile 
phases used for the separation of Yb/177Lu or the Dy/166Ho is a low concentration of acid. 
A well resolved separation of 161Tb from the Gd target was obtained that is comparable to 
what was reported by Lehenberger and co-workers4. This referenced paper utilized a 
cation exchange Aminex resin and α-HIBA as the eluent to separate 161Tb from the Dy 
target. Due to the slow flow rate ( ~0.2 mL/min), the time it took to complete the 
separation in the referenced paper is more than double what was found in this study (1.1 
h).  
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Figure 3-7.  Separation of 161Tb from a Gd (39.9 mg) target using the Ln2 resin. The 
solvent was 200 mL of 0.15 M HNO3 followed by 30 mL of 3M HNO3 at an elution flow 
rate of 4 mL/min. Under these conditions, 161Tb eluted in 30 mL of the 3 M HNO3.      
 
3.4 Conclusion 
The separation of radiolanthanides using chromatography media was evaluated. 
The extraction chromatography resin and cation exchange resins were investigated for 
separating radiolanthanides that are used for radiopharmaceutical purposes. The objective 
to remove the bulk of the irradiated Yb target from the 177Lu product was successfully 
performed using the extraction chromatography media. A sequential elution of the bulk 
Yb and trace amounts of Lu was obtained with only 26% of the 177Lu activity lost to the 
Yb sample. The separation performance was slightly affected by changes in flow rates. 
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The positive-pressure driven solvent flow exerts a high pressure resulting in resin 
compression.  This could have an adverse effect in the resin packing since the top end of 
the resin is loose, and it is possible for resin movement (compression/relaxation) during 
the separation process. 
 The column performance was evaluated at different flow rates to determine a 
reproducible elution profile of the separating elements. Although, the exerted pressure 
brought about a change in the distribution profile of Yb/Lu (an increase in the loss of 
177Lu to the 175Yb fraction with increasing flow rate), the separation of the peaks was 
consistent. The results obtained highlighted the resins robustness in the separation of 
Yb/Lu within a reasonable amount of time (1-3 h depending on the choice of flow rate). 
The separation times indicated here are associated with the Ln2 column. Further 
separation utilizing HPLC and ion-exchange column could take up to 2h. Considering the 
half-life of 177Lu, the time it takes to process the production and separation of 177Lu is 
quite reasonable. The separation of 166Ho from the Dy targets using Ln2 column was 
successful in removing the Ho from the Dy fraction. The high cross-section of the 
enriched 164Dy allows the production of the 166Ho in high yields; even using a slightly 
smaller mass of Dy targets (12 mg) than what was used for evaluating the Yb/Lu (45 mg) 
separation. The separation of small mass of the enriched target from the daughter product 
using Ln2 chromatography is advantageous since there will be less tailing of the bulk 
parent nuclide. Similar encouraging results were obtained for the separation of the 161Tb 
from the Gd target using Ln2 column.  
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3.5 Future Studies 
The separation of radiolanthanides using extraction chromatography has shown 
promising results in terms of isolating the bulk amount of the enriched target isotope 
from the irradiated target. In order to utilize column chromatography for routine 
production of radiolanthanides, the conditions that affect reproducible results in the 
separation of radiolanthanides needs further evaluations. Due to the fines present in the 
Ln2 resin, the solvent flow was performed by applying positive pressure to attain the 
desired flow rate for good separations. During the column experiments, changes in the 
bed volume (expansion and contraction; the top end of the bed volume is not restricted 
from movement) between experiments, which was caused by the positive pressure, had 
adverse effects in the separation profiles of the sample. In the work of Horwitz et al. daily 
use of the column resulted in a 5 % shift in the cut point between the Lu and Yb 
fractions.18 This change in the performance of the column could be due to the pressure 
exerted on the column that resulted in the change in elution profile of the sample. A 
column that is packed to its full capacity restricts the resin movement inside the column 
and the uniform distribution of pressure on the bed volume can assist in avoiding the 
change in elution profile of the sample. However, loading a resin having a small particle 
size (~ 40 μm) could cause pressure build up and is not ideal for packing a glass column 
with positive pressure. Therefore, solvent flow assisted with pull mechanism, instead of 
push, may be helpful in obtaining reproducible results. 
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3.6 Appendix  
Enriched Yb2O3   
Isotope 168 170 171 172 173 174 176 
Enrichment 
% <0.05 <0.05 <0.05 <0.05 <0.05 ±0.13 99.81±0.20 
Enriched Dy2O3 
Isotope 156 158 160 161 162 163 164 
Enrichment 
(%) <0.01 <0.01 0.02±0.01 0.15±0.03 1.05±0.03 1.05±0.05 98.43±0.05
Enriched Gd2O3 
Isotope 152 154 155 156 157 158 160 
Enrichment 
(%) <0.01 0.01 0.18 0.36 0.25 1.00 98.2±0.1 
Figure A 3-1. Analysis of the isotope distribution of enriched target compounds 176Yb, 
164Dy, and 160Gd  
 
 
Figure A 3-2. Separation of 177Lu from Yb targets that contains natural Yb (45 mg) with 
elution flow rate at 2 mL/min 
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Figure A 3-3. Separation of 177Lu from Yb targets that contains natural Yb (45 mg) with 
elution flow rate at 2.5 mL/min 
 
Figure A 3-4. Separation of 177Lu from Yb targets that contains natural Yb (45 mg) with 
elution flow rate at 3 mL/min 
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Figure A 3-5. Separation of 177Lu from Yb targets that contains natural Yb (45 mg) with 
elution flow rate at 5 mL/min 
 
Figure A 3-6. Separation of 166Ho from Dy targets that conatins cold natural Dy (12.6 
mg)  with elution flow rate at 4 mL/min.  
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Figure A 3-7. Picture of column chromatography separation using Ln2 resin as 
extraction media with heat exchange jacket. The flow rate of the column is controlled by 
adjusting flow gauge of a compressed N2 to obtain the desired flow rate. 
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Chapter 4  
Chemical and electrochemical reduction and separation of 177Lu from 
ytterbium 
4.1 Introduction 
Separation of radiolanthanides by changing the oxidation state of one of the two 
neighboring elements is an alternative separation method to column chromatography. For 
example, the separation of a sample containing lanthanides with multiple oxidation states 
utilizes various methodologies to isolate the radiolanthanides of interest. This chapter 
discusses the separation of Yb from Lu by reducing the Yb3+ to Yb2+ using chemical and 
electrochemical reduction techniques.  
Given the lanthanides are highly electropositive with the stable oxidation state 
being 3+ across the period, a reducing agent with high over potential is needed to drive 
the reaction to completion. The reduction of Ln3+ ions to a lower oxidization state can 
also be achieved by applying an external potential. The +2 oxidation state is only 
accessible for a few lanthanides (Nd, Sm, Eu, Dy, Tm, and Yb). Furthermore, the 
reduction potential for Sm, Eu, and Yb (Ln3+/Ln2+) redox couple is  lower (~ 1 V) than 
the reduction potential for the Ln3+/Ln0  redox coupled to generate the elemental atoms.  
Based on the reported standard redox potentials, a selective reduction of Ln3+/Ln2+ for 
Sm, Eu, Yb is achievable without driving their oxidation state to the elemental state. This 
means the other lanthanides with inaccessible divalent states can be spared in the 
reduction process, while the neighboring elements are reduced. For example, the 
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reduction potential for the redox couple Yb3+/Yb2+ is -1.05 V and that of the Yb3+/Yb0 or 
Lu3+/Lu0 is close to -2.3V, which is quiet high.1 Therefore, the selective reduction of 
Yb3+/Yb2+ can be achieved without altering the oxidation state of the Lu3+. This aspect of 
the redox property of the lanthanides can be exploited in separation processes. 
 Ln3+ Ln2+ Ln0 
Sm [Xe] 4f5 
 
[Xe] 4f6
(Ln3++ 1e →Ln2+  -1.55 V) 
[Xe] 4f6 6s2 
(Ln3+ + 3e →Ln0  -2.30 V)
Eu [Xe] 4f6 
 
[Xe] 4f7
(Ln3++ 1e →Ln2+  -0.34 V) 
[Xe] 4f7 6s2 
(Ln3+ + 3e →Ln0 -1.99 V)
Gd [Xe] 4f7  [Xe] 4f7 5d1 6s2
(Ln3+ + 3e →Ln0  -2.29 V) 
Tb [Xe] 4f8  [Xe] 4f9 6s2 
(Ln3++ 3e →Ln0  -2.30 V) 
Dy [Xe] 4f9 [Xe] 4f10
(Ln3++ 1e →Ln2+ -2.5V) 
[Xe] 4f10 6s2 
(Ln3++ 3e →Ln0  -2.29 V) 
Ho [Xe] 4f10  [Xe] 4f11 6s2 
(Ln3++ 3e →Ln0  -2.33 V)
Yb [Xe] 4f13 [Xe] 4f14
(Ln3++ 1e →Ln2+  -1.05 V) 
[Xe] 4f14 6s2 
(Ln3++ 3e →Ln0  -2.22 V) 
Lu [Xe] 4f14  [Xe] 4f14 5d16s2
(Ln3++ 3e →Ln0  -2.30 V) 
 
Table 4-1. The electron configuration of the lanthanides and the common ions with the 
redox half reactions and the standard redox potentials in parentheses1. 
The chemical separation of the lanthanides is not without disadvantages. The 
chemical instability of the divalent lanthanides due to their high oxidation potential is a 
stumbling block in the separation process. They are considered as potent reducing agents 
due to their ability to reduce solvent media such as water. In this regard, the separation 
process of radiolanthanides is limited to anhydrous solvents under inert atmosphere. In 
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order to separate the two elements (Yb and Lu) by reducing the Yb3+ to Yb2+, while the 
Lu remains in the 3+ oxidation, special attention is given to solvent media (the grade and 
quality), the counter ions present for stabilizing the Ln ions in solution, and chemical 
media applied to separate the radiolanthanides with two different oxidation state . The 
early studies conducted to separate Yb from Lu using various reducing methods are 
chronicled below. 
In the early 1930’s L.F. Yntema and R.W. Ball were able to reduce Yb3+ to Yb2+ 
and isolate YbSO4.2 A lanthanide chloride solution was prepared by dissolving 10 g of 
lanthanide oxide in HCl(aq), and the excess solvent removed by evaporation, while the 
remaining YbCl3 was dissolved in H2SO4. In the electrolytic cell, which contained the Hg 
cathode and Pt anode in 0.05 N HCl (electrolyte), the sample containing YbCl3 was 
added. A current of 0.10 A, with a current density of 0.025 A/cm2 at the cathode, and a 
voltage of 110 V was applied to reduce the Yb3+ to Yb2+  and resulted in the precipitation 
of YbSO4. Similar experiments were conducted by W. Prandt to produce Yb2+ based on 
the previous work by Yntema and Ball.2 The electrolytic reduction was carried out in an 
aqueous solution of Yb/Lu sulfates using a Hg cathode and a Pt anode. The current was 
maintained between 0.20 and 0.40 A, the voltage drop was 110 V, and the temperature 
ranged from 40 to 60 ºC. The purity and percent recovery of the YbSO4 was not reported. 
In 1963, Asprey et al. investigated the formation of YbSO4 over  a Hg pool 
cathode.3 An electrolytic cell was set up containing a Hg cathode and a Pt anode. During 
electrolysis, the anode tube was dipped into the rare earth solution. A current density 
between 0.02 and 0.06 A/cm2 and a voltage between 6 and 12 V were used. The authors 
reported the formation of YbSO4 within a few minutes and they were able to extract the 
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YbSO4. However, due to the instability of the divalent salts, the precision of the 
measurements were of poor quality, but still sufficient for characterization. Separation of 
Eu from the lanthanides by reduction followed by column chromatography was 
investigated by Moskvin et al.4  In his report a mixture of Ln3+ in HCl/NH4Cl was loaded 
on a Jones reduction column and the subsequent elution was followed by column 
chromatography media containing HDEHP (fixed on teflon). This multistep separation 
demonstrated the reduced Eu2+ eluted first while the other Ln3+ species eluted later. The 
report also indicated that trace amounts of Eu2+ could not be separated from the mixtures 
of Ln3+ due to oxidation of Eu2+ to Eu3+ by elementary oxygen.    
 Although, the application to lanthanides in the referenced literature is different 
from what is pursued in this study, the following reports have described the successful 
reduction of Yb3+ to Yb2+ by electrochemical reduction, which is otherwise difficult to 
accomplish under ambient conditions. Rabockai reported the reversible electrochemical 
reduction of Yb3+ in aqueous solutions at various temperatures.5 This report utilized a 
mercury pool and NaClO4 as the working electrode and supporting electrolytes, 
respectively. Mercury is considered an incompatible chemical for radiopharmaceutical 
applications due to health concerns. Also, the aqueous supporting electrolytes have 
unfavorable effects on the stability of Yb2+ for bulk reduction and separation processes. 
Another reduction method reported by Nakashima et al. explored photon excitation of 
Yb3+ to reduce it to Yb2+.6 In his early publications, Nakashima indicated the irradiation 
of Eu3+and Sm3+ ions in solutions by a laser assisted pulse excitation that resulted in the 
reduction of Sm3+ to Sm2+ and Eu3+ to Eu2+. This investigation was later translated to Yb 
reduction chemistry and reduced Yb3+ to Yb2+ by laser irradiation. This paper indicated 
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an increase in concentrations of Yb3+ resulted in incomplete reductions. Since the 
separation of the reduced lanthanides was not within the scope of their investigation, no 
further data is available.6 
 The objective of the current study is to isolate the bulk of the irradiated enriched 
Yb3+ target from 177Lu3+ in a multistep separation process. If, by some simple (one-stage) 
process, one could remove the Yb2+, partially or entirely (chemically or by use of 
chromatography media), the subsequent purification process to obtain high specific 
activity of Lu3+ would be made easier. So far, encouraging results have been achieved in 
the separation of large amounts of Yb3+ target (45 mg) from 177Lu using extraction 
column chromatography. The separation of Yb3+ from Lu3+ using chromatography 
column (Ln2 resin) generates a large amount of radioactive waste containing 
concentrated acids. Also, such a process takes hours of sample preparation and column 
run time that exposes workers to radiation.  In order to find a more efficient separation of 
175Yb/177Lu, a multistep separation process that includes the reduction of Yb3+ to Yb2+ 
followed by a separation technique including selective precipitation of Yb2+, column 
chromatography, or selective complexation is described. Accordingly, the work in this 
chapter is separated into two sections: (1) determine the best reduction method to obtain 
complete reduction of Yb3+and (2) evaluate the separation techniques to isolate the 
divalent Yb2+ from Lu3+.  
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4.2 Experimental 
4.2.1 Chemicals and Reagents. Sources of reductant metals of varying mesh sizes and 
purity levels are listed as follows: Mg (99 %, 325 mesh, Strem Chemicals (Newburyport, 
MA)); Y (99.9 %, 40 mesh, 325 mesh, Sigma Aldrich (St. Louis, MO)); Zr (99.5 %, 325 
mesh size, Sigma-Aldrich (St. Louis, MO)); and Al (99.5 %, 325 mesh, Alpha Aesar 
(Newburyport, MA)). Anhydrous YbCl3 (99.9%) and Yb(OTf)3 (99.9%) were acquired 
from Sigma-Aldrich (St. Louis, MO). Lutetium chloride was purchased from Alpha 
Aesar (Newburyport, MA). All solvents used for the reduction of Yb3+ were anhydrous (≥ 
99.5 % purity) and were obtained from Sigma-Aldrich (St. Louis, MO). 
4.2.2 Preparation of Yb compounds for the reduction of Yb3+ to Yb2+. The reduction and 
separation experiments were conducted in a controlled atmosphere glove box operating 
under argon.  A weighed amount of ytterbium compound (YbCl3 or Yb(OTf)3) was 
dissolved in either MeOH or EtOH. Yb(acac)3 was prepared following the procedures 
described in the literature.7 Briefly, Yb(acac)3 was prepared by adding a mixture of 3 
mmol of acetylacetone (redistilled under argon following the chemical purification 
procedure)8 in 95% ethanol to a stirring solution of YbCl3 (1 mmol) at 40 ◦C. The product 
was used for the reduction of Yb3+ without isolation. 
Procedure for the chemical reduction of Yb3+. The chemical reduction of Yb3+ in 
solution was performed using reductant metals. The metals and their respective standard 
redox potentials are listed below in Table 4-2.  
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Reductant metals Standard redox potential (V) 
Mg → Mg2+ + 2e- +2.38 
Y → Y3+ + 3e- +2.37 
Hf →Hf4+ + 4e- +1.70 
Ti → Ti2+ + 2e- +1.63 
Al → Al3+ + 3e- + 1.6 
Zr → Zr4+ + 4e- +1.5 
Mn → Mn2++ 2e- + 1.18 
Table 4-2. The standard redox potential of metals utilized for reducing Yb3+ to Yb2+is 
referenced.1  
Preliminary experiments were conducted to reduce the Yb3+ to Yb2+ using glass columns 
filled with the metals to maximize the contact surface area and the reaction time between 
the metal and the Yb3+ sample. This setup was helpful when using large particle size 
metal powders that are porous for the loaded sample to elute by gravity. The other 
advantage of using a reduction column is that it is convenient to link the reduction 
column to a separation column that could be packed with a cation exchange resin or an 
extraction column so that the successive reduction and separation step minimizes the 
sample exposure to air as shown in Figure 4-1. 
 
Figure 4-1. Picture of the reaction setup of reductant column connected to the separation 
column filled with a chromatography media. This setup uses a solvent reservoir to 
transfer the eluting solvent (EtOH/ACN) to the column. 
Metal reductants (Mg, Zr, or Y) 
 (a) DOWEX AG 50W-X12 
[200-400mesh (H-form)] 
(b) Chelex BioRad  
(c) Na2SO4 (powder)
The distribution of the 175Yb 
and 177Lu in the collected 
fractions are evaluated  
Loaded sample + solvent 
YbCl3 spiked with 175Yb/177Lu 
EtOH /ACN (40:60)
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To eliminate column blockage by the small particle sized metal powders, reaction 
mixtures that contained fine metal powders and the sample were stirred for the duration 
of the reaction followed by isolation of the liquid from the reaction mixtures to perform 
the separation process.  The reductant metals were rinsed with 2 mL of the solvents that 
were used to dissolve the Yb salts. The sample containing Yb compounds (0.3 mmoles) 
was dissolved in 2 mL of MeOH or EtOH. The reaction mixture containing the reductant 
metal powders and the Yb salts were stirred and evaluated (by iodimetric titration; see 
below) by withdrawing the solutions from the reaction mixture with a syringe and 
filtering through a 0.22 μm Whatman filter disks.    
4.2.3 Quantification of the reduced Yb2+.  The iodimetric titration method was used to 
determine the amount of Yb3+ reduced by the metal reductants. A known amount of the 
Yb2+ Cl2 or Yb2+(OTf)2 (green colored samples) was isolated from the redox reaction 
mixture and titrated with a fresh solution made of iodine dissolved in a solvent mixture of 
EtOH and ACN (35:65 v/v). In the iodimetric titration of Yb2+, the solution containing 
the Yb2+ was stirred with a known volume of I2 that was added to the mixture that 
changed the green colored solution to colorless; the excess I2 was titrated with a 
standardized solution of sodium thiosulfate. The number of moles of Yb2+ was 
determined by subtracting the moles of thiosulfate used to complete the titration from the 
moles of I2 added to the mixture (Equations 4-1 & 4-2 show the chemical reaction 
between Yb2+ and I2). The efficiency of the reductant metal was determined by taking the 
moles of Yb2+ divided by the total moles of Yb3+used for the reaction and multiplied by 
100 to establish the percent yield.  
       2Yb2+ + I2 → 2Yb3+ + 2I-                                Equation  4-1 
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I2 excess+ 2S2O32- → 2I- + S2O62-        Equation 4-2 
                                       
4.2.4  Electrochemical Reduction. The electrochemical data were obtained with a Bio-
analytical Systems Inc. (BAS) CV-50 instrument. The non-aqueous electrolytes 
(tetraethylammonium chloride, tetrabutyl ammonium perchlorate electrochemical 
analysis, > 99 % from Sigma Aldrich, St Louis], and tetrabutylammonium 
tetrafluoroborate (ACS grade 98% from Sigma Aldrich)) were dissolved in anhydrous 
ethanol/acetonitrile solutions to make 1 mM concentrations. A non-aqueous 0.1 M 
Ag/AgCl reference electrode was prepared following a referenced procedure 9). The 
working electrodes evaluated were glassy carbon, carbon paste, and titanium wires 
(99.9% metal basis; 0.127 mm, from Alpha Aesar ). The carbon paste working electrode 
was prepared by following a literature method using glassy carbon powder and mineral 
oil.10 The counter electrode was a platinum wire (Bioanalytical Systems).  The cyclic 
voltammetry experiments were evaluated at scan rates of 50 mV/sec and 100 mV /sec. 
The applied potential operating window for the CV experiments was 100 mV to -2000 
mV.  
 For the bulk electrolytic reduction of Yb3+, H-cell electrochemical glassware was 
used and the cathodic and anodic compartments were filled with tetraethylammonium 
chloride (electrolytes) in anhydrous EtOH/ACN mixtures, while YbCl3, Yb(OTf)3, or 
Yb(acac)3 were added to the cathodic cells. For the bulk electrolysis the glassy carbon 
paste and a platinum rod were used in the cathodic and anodic compartments, 
respectively. The reaction vessel was purged with argon gas prior to use and continuously 
purged during the course of electrolysis.  
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4.2.5 Separation of Yb2+ from Lu3+by selective precipitation. Ytterbium chloride (0.38 
mmole) was dissolved in 2 mL of MeOH/ACN that also contained radioactive 
175Yb/177Lu. This sample was then added to Mg or Y (100 mg) metal reductants and the 
reaction mixture was stirred for 30 min. The solution was isolated from the mixture and 
added to tetramethylammonium sulfate (1.1 mmole) that was dissolved in 1 mL of 
MeOH. An instant precipitation following the addition was observed. The reaction 
vessels were centrifuged and the supernatant and pellet fractions were separately counted 
to determine the distribution profile of 175Yb and 177Lu in each of the fractions.  
4.2.6 Separation of Yb2+ from Lu3+using chromatography media. Labset glassware kits 
from Chemglass with screw cap ends were assembled for the reduction and separation 
experiments (Figure 4-1). A constant flow of solvent (EtOH/ACN mix), purged under 
N2, was passed through the joined glass columns. The first column was filled with the 
reductant metals (Mg, Zr, or Y) and the second was filled with the separating reagents 
(DOWEX AG 50W x 8, Chelex-100 resin, or Na2SO4).  A sample containing YbCl3 was 
spiked with 175Yb/177Lu and loaded onto the column using a syringe and allowed to react 
with the reductant metal, and then eluted onto the separation column by gravity solvent 
flow.  
  4.2.7 Separation of Yb2+ from Lu3+by complex formation. Ytterbium chloride (0.38 
mmole) was dissolved in 2 mL MeOH/ACN mixture and spiked with 175Yb/177Lu (50 μL, 
622 μCi). The sample was added to a reductant metal (Mg, 100 mg). After the reaction 
was stirred for 30 min, the solution was isolated, filtered through a Whatman filter disk, 
and 500 μL of the Yb/Lu reaction mixture was added to 0.2, 0.3, 0.5, or 0.8 M HDEHP in 
500 μL. At high concentrations of HDEHP (0.5 and 0.8M), multiple layers of solution 
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formed. The samples were centrifuged to separate the layers and an aliquot from each 
layer was evaluated for 175Yb/177Lu by spotting on C-18 reversed phase TLC plates to 
evaluate the Yb2+ vs Yb3+ HDEHP speciation.  The developing solution for theTLC plates 
was 20/80 acetone/hexane. The TLC plates were analyzed using an AR-2000 Bioscan. 
The Yb/Lu sample that forms a complex with HDEHP moved toward the solvent front on 
the C-18 reversed phase TLC plates, whereas the Yb/Lu that did not form a complex with 
HDEHP remains at the origin.  
4.3 Results and Discussions 
The multistep separation process involving chemical or electrochemical reduction 
of the Yb2+ followed by separation from the Lu3+ was evaluated. The first step was to 
determine the effectiveness of the method of reduction (Yb3+ to Yb2+) that leads to the 
complete reduction of Yb3+, whereas the second step explored separating the two species, 
Yb2+ and Lu3+ that differed in their oxidation states.  
4.3.1 Electrolytic reduction of Yb3 to Yb2+. In order to achieve complete reduction of 
Yb3+ to Yb2+ a set of experiments was performed by applying a potential to the Yb3+ 
compound.  The different redox inert metals that were used as electrodes did not show 
evidence of reducing the Yb3+ under various sets of conditions, namely prolonged time of 
current flow, solvent mixtures, and potential. By using the glassy carbon electrode, a 
reversible Yb3+ -Yb2+ Clx couple (E◦= -0.8 V) was observed by the cyclic voltammetry 
(Figure 4-2). In addition, Yb(acac)3 resulted in a similar reversible scan with the 
reduction potential close to -1.6 V. The higher potential recorded for complexed Yb3+ 
compounds indicate that the coordinating ligands are acting as electron donors, resulting 
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in an increase in potential for the reduction to occur. This result indicates that alternative 
methods that could assist in the dissolution of Yb salts in organic solvents by forming 
complexes with ligands is not ideal  due to the higher potentials required to reduce Yb3+. 
A study reported by Dennis et al. showed the changes in the Ce3+/Ce4+ redox couple can 
be produced by changing the chelating ligand.11 Based on this report, the electron 
withdrawing effect of the ligand donor atoms contributed to slightly higher reduction 
potentials required to reduce the lanthanides ions. The electron density effect is 
pronounced in lanthanide ions because the f-orbitals are inaccessible to the binding 
electrons from the ligand orbitals.  
Previous studies involving electrolytic reduction of Sm3+ and Yb3+ compounds.             
A successful reversible electrolytic reduction of Yb (OTf)3 has been reported by Parrish 
et al. with redox potentials varying between the Yb(OTf)2 and YbI2 compounds12 . This 
report suggested that the supporting electrolytes in acetonitrile (T-Bu4NX; X = Cl-, I-, and 
Br-) undergo ligand exchange with the triflate and the halide forms of ytterbium. The 
experimental redox potential for Yb(OTf)3 in the presence of a tetraalkyl ammonium 
iodide and bromide electrolytes was -1.2 and -1.7 V, respectively.  
An attempt to perform bulk electrolysis on Yb3+ using carbon paste as the cathode 
did not exhibit reduction. The solvent mixture used (MeOH/ACN) to dissolve the Yb3+ 
and the electrolyte was not compatible with the carbon paste. The carbon paste, tantalum, 
and titanium metal working electrodes did not show even psuedo-reversible cyclic 
voltammetric scans. A flat scan swipe that went through a highly negative potential 
without indication of any sort of peak suggested the reduction of the Yb3+ ion did not 
occur. This was true for YbCl3 and Yb(OTf)3 compounds.  Voltammetric scans similar to 
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the one shown on Figure 4-3 were observed and show the ineffectiveness of the working 
electrodes discussed.    
 
Figure 4-2. Cyclic voltammetry of YbCl3 in TEACl as the supporting electrolyte and 
MeOH/ACN as the solvent using glassy carbon as the working electrode. 
 
 
Figure 4-3. Cyclic voltammetry of YbCl3 in TEACl using Ta as a working electrode. 
Similar scans were observed for Ti metal wire as working electrode with the 
Yb(OTf)3 analyte.  
The calculated redox potential of Yb(OTf)3 vs Ag/AgCl reference electrode in 
EtOH/ACN solvents is -0.715 V. The total potential required for the complete reduction 
of Yb3+ was close to -1.0 V.  A bulk electrolysis was conducted using glassy carbon paste 
as the working electrode with a potential of -2.5 V, well above the experimentally 
determined value. The result from the bulk electrolysis experiment, showed no indication 
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of reduced Yb2+ in the solution. After a prolonged experiment of applying potential to the 
Yb3+ compound, gradual accumulation of insoluble particulates covered the electrode 
surface. This could be due either to the electrode incompatibility with the solvent mixture 
(EtOH/ACN) or from the electrolytes decomposition at higher voltage. There was not a 
discernible current flow or observable color change from using the glassy carbon paste as 
the working electrode. 
4.3.2 Chemical Reduction of Yb3+ to Yb2+. The efficiency in reducing the Yb3+ to Yb2+ 
was related to the strength of the standard reduction potential of the metals used as 
reductants. Higher mesh number or lower particle size was effective in reducing Yb3+ due 
to the high surface area.  The reduction of Yb3+ with high yield was investigated to 
determine the optimum conditions. Among the variables evaluated to accomplish the 
objectives, a series of changes in the reagents used (YbCl3, Yb(OTf)3, and Yb(acac)3), 
metal reductants, temperature, and solvent mixtures were investigated and found to have 
exhibited pronounced effect in the amount of  Yb3+ reduced. The reason for evaluating 
only these listed ytterbium compounds were because of the limitation in the practical 
work up to prepare the Yb targets. In order to maintain the Yb2+ stable in solution, the 
starting Yb compound has to be anhydrous. Of the three forms of the Yb compounds 
evaluated, the Yb(OTf)3 could easily be dehydrated and reduced to its +2 oxidation 
state.13 
 The amount of Yb3+ reduced by the reductant metal was directly related to the 
standard redox potential of the metals used. Although all of the evaluated reductant 
metals have a redox potential well above the potentials needed to reduce Yb2+, the 
solvent system utilized for the reduction might weaken their potency as a reductant.  
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Magnesium and yttrium metals afforded reduction of Yb3+ to Yb2+ with the highest 
yields. A vigorous reaction was often observed when using these two metals resulting in 
an instant color change to bright green, which is indicative of reduction of Yb3+. While 
the other metals (Zr, Hf, Ti, and Al) have sufficient potential to reduce Yb3+, the yield 
from the reduction process was small to nothing. A slight faint green color was observed 
on the surface of the metal but the amount of Yb2+ formed was not enough to quantify. 
Table 4-2 below lists the percentage yields obtained by using metals for the reduction of 
Yb3+. 
 Solvent 
mixtures 
% Yield of Yb
2+
  
Mg Y Mn Zr Hf Ti Al 
YbCl
3
  EtOH/ACN 
(35:65) 72.0 ± 5  90.0 ±7 20±2.5 0 0 0 0 
MeOH/ACN 
(35:65) 60.0 ± 2  87±1.3 0 0 0 0 0 
Yb(OTf)
3
  EtOH/ACN 
(35:65) 10.0 ± 1.8 0 0 0 0 0 0 
MeOH/ACN 
(35:65) 0 0 0 0 0 0 0 
Table 4-2. The result from the reduction of Yb3+using reductant metals in different 
solvent conditions. The amount of Yb2+ obtained after the reduction was determined by 
iodometric titration. In some of the evaluated reductant metals there was no observable 
color change in the reaction mixtures.  
4.3.3 Counter ion or complexing ligand effect(s) on the reducing metals. The counter 
ions or complexing ligands of Yb3+ have an effect on the redox potential of Yb due to 
their interaction with the Yb3+ ion by either donating or withdrawing electron density.14 
For this reason, the redox potential required to reduce Yb3+ varies depending on the form 
of Yb3+ (YbCl3, Yb(Otf)3, or Yb(acac)3) used for the reduction process. Ytterbium nitrate 
is an alternative source used for the target irradiation for production of 177Lu. However, 
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these studies did not include the NO3
- due to its redox susceptibility in the presence of 
reductants and formation of NOx species.15  
  In general, from the set of Yb3+ starting materials used for the reduction process, 
YbClx (MeCN)yCl- and Yb(MeCN)3+ (OTf)3 demonstrated reduction by using metal 
reductants. However, of the two forms of Yb3+ compounds, the triflate takes a longer 
time for the reduction to occur (2 h). This was evident after using Mg or Y as the 
reductant metals.  
4.3.4 Solvent effect. Since the reduced Yb2+ is easily oxidized back to Yb3+ in the 
presence of water or oxygen, the solvents used to dissolve the Yb3+ salts must be 
anhydrous and oxygen free. The ytterbium salts that were utilized for this study were 
soluble in methanol and ethanol, and partially soluble in isopropyl alcohol. Pure alcohol 
solvents were superior in dissolving the Yb salts, but the strong reaction on adding the 
metal reductants that evolved heat and gas followed by a sudden disappearance of the 
green color suggested Yb2+ was oxidized to Yb3+ by undergoing the following chemical 
reactions. 
Mg(s) + 2ROH  Mg(OR)2 + 2H+ R= -CH2CH3 or -CH3 
H+ + 2e- → H2 (g) 
 Magnesium is capable of forming alkoxide species as the above equation 
indicates.16-18 Also, the formation of the Mg-alkoxide species proceeds at elevated 
temperatures. This reaction produces H+ that can undergo a one electron reduction to 
form H2 gas (H2 gas bubbles were observed during the reaction). Magnesium metal and 
110 
 
Yb2+ are potent in reducing H+ to H2, since Yb2+ ion was in the liquid phase, it is safe to 
assume Yb2+ reduced H+, resulting in oxidation back to Yb3+. 
                In order to circumvent the aggressive reaction of the metals in the presence of 
Yb3+ compounds that leads to the oxidation of Yb2+ to Yb3+, various modifications were 
made to control the random temperature changes. By cooling the reaction mixtures using 
external cooling mantles (also dry-ice incubation), heat and bubble occurrences (that 
were evident in reactions conducted in room temperatures) were eliminated. However, an 
attempt to keep the reaction mixture at < -10 ◦C resulted in the amount of Yb2+ formed 
reduced to 38% ±0.02.  Other approaches used to ease the rapid temperature increase 
included the use of solvent mixtures such as alcohols, acetonitrile, and tetrahydrofuran to 
accommodate the solubility issues of Yb3+ salts and conduct the reaction under cooler 
temperatures. Table 4-3 lists the solvent mixtures examined to obtain the highest yield of 
reduced Yb2+. There were a few solvent mixtures (e.g., MeOH/cyclohexane) that were 
either incompatible or did not keep the Yb3+ salt in solution. While THF and 1,4-dioxane 
are regarded as complexing solvents that should stabilize divalent lanthanides,14 the Yb3+ 
compounds constantly crashed out of solution in these solvents and required alcohol 
mixtures to keep the Yb3+ salt in solution. The EtOH/ACN mixtures were the ones that 
gave the highest yield of Yb2+, (72 % and 90% using Mg and Y metals, respectively). 
The advantage in using solvent mixtures is that in the presence of a proton 
acceptor solvent (nitrogen of the ACN) the proton of the alcohol will tend to form 
hydrogen bonds with the nitrile groups of ACN.19 As a result, the oxidized metal (e.g., 
Mg2+) will be stabilized by forming an alkoxy bond. Also, formation of a hydrogen bond 
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with the nitriles will lessen the chance of the dissociated protons being reduced to H2 gas 
by Yb2+, which is an unfavorable outcome that leads to oxidation of Yb2+ to Yb3+. 
 
Solvent system  
Percent Yield 
of Yb2+  δ observation 
MeOH 32.0 ± 4.0   
EtOH 36.3 ±2.0   
THF    Not soluble 
  
10% MeOH/THF    
40% MeOH/THF 61.37 ±2.0 
10% MeOH/ACN     murky solution 
35 % MeOH/ACN  40.33 ±3.0   
40% MeOH/ACN  32.33 ±4.0   
50% MeOH/ACN  27.67 ±2.0 
25 % MeOH/EtOAc 23.36 ±2.0   
40% MeOH/dioxane  0     
10% EtOH/THF  0     
40% EtOH/THF  0     
10% EtOH/ACN  0
Not soluble 
 
25% EtOH/ACN  39.00 ±4.0   
35% EtOH/ACN  72.00 ±5.0   
40% EtOH/ACN  68.33 ±3.0   
40% EtOH/ACN   
ascorbic added  0   Murky solution 
50% EtOH/ACN  56.00 ±5.0   
28% EtOH/dioxane 0     
40% EtOH/dioxane 0     
40% MeOH/Cylohexane     
not compatible  
with alcohol 40% MeOH/hexane     
40% MeOH/toluene     
Table 4-3 Reduction of YbCl3 using Mg as the reductant metal. Iodometric titration 
methodology was applied to determine the amount of Yb2+ in solution. (δ = standard 
deviation with n = 3)  
4.3.5  1,4-Dioxane and THF as complexing solvents. The effects of complexing solvents 
such as 1,4-dioxane and THF on the Yb2+  was prominent in stabilizing the reduced Yb2+. 
In the early publications by Clifford et al. there was a suggestion that complexing 
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reagents such as THF stabilized the rather short-lived Sm2+ or Yb2+ compounds 14, 20. 
When using THF as a solvent mixture to stabilize the Yb2+ ion, however, insoluble 
particulates formed on the surface of the reductant metal. This observation suggested the 
presence of THF could have facilitated Yb2+ precipitation. Similar observations were 
reported by Collin et al. in an attempt to reduce Sm3+ to Sm2+ and indicated occasional 
precipitation occurred on the surface of the reductant metal when they used THF as the 
solvent.21  
4.3.6  Separation of 177Lu from Yb. The reaction mixture containing Yb3+ compounds 
were spiked with 175Yb/177Lu and the separation of the Yb from Lu was evaluated 
counting the samples using HPGe and analyzing the emitted energies spectrum. The 
separation was classified into three parts: column separation, solid phase extraction, and 
liquid-liquid extraction using complexing reagents. After allowing the Yb3+ compounds 
to react with metal reductants, the second step was to (1) pass the reaction mixture 
through a column containing an ion exchange resin, (2) extract a complexed Yb2+ from 
the Lu3+ reaction with the reductant metals, and (3) extract the reduced Yb2+ as a solid. 
(1) The column separation was conducted using Chelex and DOWEX resins 
(according to the manufacturer’s specifications, the resins are compatible with the solvent 
system used in this experiment (i.e., alcohol/ACN mixtures)). The reason for using cation 
exchange resins was to separate the Yb2+ from the Lu3+ (the expected order of elution 
profile would be Yb2+ first followed by 177Lu3+). The Chelex resin is selective for divalent 
metal ions due to the binding affinity of the metals to the carboxylic acid groups of the 
resin at a specific pH. The difficulty encountered in using resins as the chromatography 
media was that they are designed to perform well in wet media (i.e., in the presence of 
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water). This could possibly be the reason why the separation of the reduced Yb2+ from 
177Lu using chromatography media did not perform well since the Yb2+ is easily oxidized 
in the presence of water. An attempt to dry the resins (Chelex or DOWEX 50W X 4) 
caused column channeling during column equilibration, which made the subsequent 
separation trials unsuccessful. Both Chelex and DOWEX chromatography resin that are 
capable of binding lanthanides with high affinity22-24 managed to only retain 40 % of the 
Yb/Lu, whilst the remaining activity (60% of the Yb/Lu with an equivalent ratio as the 
loaded sample) passed through column. 
4.3.7  Separation of Yb/Lu by complexation. Solvent extraction using phosphonates have 
been reported for removing rare-earth metals from reaction mixtures.25-26   Di-2-
ethylhexylphosporic acid (HDEHP) is used to extract lanthanides in non-polar organic 
phases. In the case of La HDEHP complexation, the Ln3+ bonds the HDEHP with the 
HDEHP forming hydrogen bonds with the adjacent phosphates (Figure 4-4). The 
differences in the oxidation number between Yb2+ and Lu3+ could potentially result in 
forming HDEHP complexes that differs by the number of coordinating HDEHP (Yb2+ 
and Lu3+). The alkylated branched chains of HDEHP with six carbon atoms per chain are 
more lipophilic and have a stronger affinity for hydrocarbons.  One approach investigated 
was to add HDEHP to the reaction mixtures containing the reduced Yb2+ /Lu3+ and 
isolate Yb2+ from the Yb3+complex using reversed phase C-18 plates. Complexed Ln3+ 
moves with the solvent front with mixtures of organic solvents (hexane/acetone) as a 
mobile phase and since there was only one observed peak by TLC, the Yb2+ may have 
been oxidized in the presence of the phosphonate groups. The chemical equation below 
indicates the dissociation of H+ from the Ln-ligand reactions.  
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Ln3+ + 3(HDEHP)2 = Ln(HDEHP)3 +3H+ 
The dissociating hydrogen ions from the phosphonate groups of the HDEHP 
could potentially oxidize the Yb2+, resulting in the formation of the trivalent Yb3+ 
HDEHP complex.  
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Figure 4-4. Structure of Ln3+(HDEHP)3 complexes.25 (R= hexyl) 
4.3.8  Separation by solid extraction. The studies reported by Bilewicz et al. and 
Chakravarty et al. discuss the efficiency of a multistep separation of the 177Lu from 
irradiated Yb3+ samples by reduction and solid state extraction. 27,28  The separation step 
that follows the reduction step takes advantage of the selective precipitation of Yb2+as the 
insoluble YbSO4. Although, each report used a different reduction method (Bilewicz used 
sodium amalgam (Na/Hg) and Chakravarty used electrolysis with mercury as a cathode to 
reduce the Yb3+ to Yb2+), both studies reported successful separation of the Yb from the 
177Lu owing to the insoluble YbSO4 or low level deposition of 177Lu in the Hg phase 
(Bilewicz reported 73 % total recovery of 177Lu, while Chakaravarty reported the 
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extraction of 177Lu was ~99 % yield). Therefore, an attempt was made to capture the 
YbSO4 in the solid state. A diagram of the reduction of Yb3+ and separation of Yb2+ from 
Yb3+ process is shown below in Figure 4-5. 
Mg powder
Sample injection port
N2 inlet
YbII SO4
Frit
(CH3)3NSO4/
NH4SO4/
H2SO4  
Figure 4-5. Separation of Yb2+ from Lu by reduction using reductant metals (e.g., Mg) 
and precipitation of the divalent Yb with sulfates. 
The precipitation of Yb2+ in the presence of sulfates that are soluble in the solvent 
mixtures (40/60: EtOH/ACN) conditioned to keep the Yb3+ salts in solution and yield the 
maximum reduction of Yb3+ was investigated. The tetraalkylammonium sulfates (TMAS) 
and sulfonates were the primary reagents chosen for the Yb2+ precipitation process. The 
selective precipitation of Yb by the sulfates did not yield the desired outcome as both 
Yb3+ and Lu3+ precipitated out of solution. This suggests that in order to selectively 
remove Yb2+ as YbSO4, the solvent has to be aqueous.  
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4.4 Conclusion 
Electrochemistry. The reduction of Yb3+ to Yb2+ by applying a potential to the sample 
has been evaluated. The electrodes chosen to perform the reduction of the Yb3+ were 
either incompatible with the solvents (strong organic solvents) or decomposed 
electrolytes at higher potentials or passivation of the surface of the electrode was 
observed. The electrolyte decomposition significantly hindered the bulk electrolysis. The 
cyclic voltammetry experiment to reduce Yb3+ to Yb2+ resulted in reversible scans for the 
YbCl3 using glassy carbon electrodes to enhance the surface area. The bulk electrolysis 
using carbon paste electrodes, however, encountered electrode surface erosion due to the 
interaction between the solvent (ACN) and the carbon paste.  
Chemical reduction of Yb3+ to Yb2+. Based on what has been evaluated thus far, the 
chemical reduction of Yb3+ to Yb2+ is ideal in terms of its chemical safety and its 
performance in reducing the bulk of the Yb sample. Although, the amount of Yb used in 
the experiments is slightly higher (100 mg) than what is regularly used in similar 
referenced literatures (~ 50 mg), the chemical yields obtained from this reduction system 
are encouraging. The separation of Yb2+ from the Lu3+ by selective precipitation has been 
reported by Bilewicz.27 Following this report, the current study attempted to isolate the 
reduced Yb2+ by precipitation but was unsuccessful in selective precipitation of Yb2+. The 
solubility of divalent YbSO4 in aqueous solvent is less than trivalent Yb2(SO4)3, however, 
since the study utilized organic solvents, the precipitation using sulfates was not selective 
for Yb2+. The precipitation of the sample by tetraalkyl sulfates resulted in precipitation of  
Yb2+/3+ and the Lu3+, which is an undesired outcome as the objective of the separation 
process was to isolate the Yb2+ in solid state for debulking purposes and the Lu3+ in the 
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liquid phase. Due to the high water content of the chromatography media, the reduced 
Yb2+ compounds were instantly oxidized on contact with the cation exchange resins. 
Conversely, anhydrous ammonium sulfate powders that were loaded on a column in the 
hope of forming the YbSO4 resulted in elution of both Yb and Lu without retention on the 
column.   
The multistep separation of the Lu3+ from the Yb3+ targets offers convenience in 
handling and processing radiolanthanides by minimizing the processing time and avoids 
generating high volumes of unwanted, radioactive wastes as is the case with column 
chromatography. Also, the solvents utilized for the reductions can easily be removed 
from the sample due to their low boiling points. It has been shown from this experiment 
that Yb3+ can be readily reduced with the reductant metal Mg and Y. 
4.5 Future Studies 
  The multistep separation of 177Lu from the Yb3+ that involves reduction of the 
Yb3+ has been explored. The separation of the divalent Yb from the Lu3+ required 
attention since the Yb2+ redox unstable, hence the chemical utilized for the separation has 
to be non-aqueous and handled under inert atmosphere. Although, the current separation 
by complexation did not yield the desired outcome, it is the conceivable option to 
perform the separation of Yb form Lu by picking ligands that are redox active. There 
were various attempts made to stabilize the reduced Yb2+ during the separation process. 
But it was difficult to fulfill the objectives due to Ln ions are attracted to oxy-ions that 
can easily oxidize the Yb2+.  Therefore, it is rather beneficial to pick a ligand that 
undergoes redox and forms a stable complex thereby changing its chemical structure as a 
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result of its complexation with Yb2+. This approach is more advantageous since the Lu3+ 
does not participate in the redox reaction and can be isolated in the solvent of choice 
(even in aqueous media), because guarding the Yb2+ from oxidation is no longer needed. 
The types of ligands that undergo one electron reduction and form stable 
complexes with carbonyl functional groups have been well explored in the organic 
chemistry in which divalent metal ions participate in the reactions as catalysts.29 A review 
article that covered the catalytic reduction of highly conjugated ketones elaborated on the 
various methods utilized to obtain a pinacole-coupled product. Figure 4-6 shows a 
general reaction that represents one electron reduction of ketones by catalytic Ln2+ ion to 
result in lanthanide pinacolates.  
 
Figure 4-6. Basic mechanism of pinacol coupling reactions 
The focus on this reaction scheme is the intermediate metal pinacolates, and 
depending on the steric effect from the conjugated ligand, the yield in forming a stable 
pinacolate compound can increase. The yield from the one electron reduction of the 
fluorenone and benozophenone results in a ketyl intermediate. The product from the 
pinacol coupling reaction (2) could only be formed in the presence of metals at lower 
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oxidation states acting in a single electron transfer. A trivalent lanthanide may form 
product (3) but will not be part of the product (2) since each of the coupling adduct 
comes in with a ketyl radical as indicated in the intermediate (1). A number of reports 
used either Sm or Yb metals as the catalytic reductants and while most of them chose the 
metal as the source of the reductant species, there are a few reports that explored the 
options of using divalent Sm or Yb to reduce the carbonyl oxygen.30 By applying the 
pinacole coupling reaction to the separation of Yb/Lu, the arduous work to protect the 
oxidation of Yb2+can be avoided. 
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